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ABSTRACT 
The aging process is typically associated with loss of muscle mass, strength, and 
function.  At a certain threshold, low levels of muscle mass, strength, and function are 
considered a disease called sarcopenia, which is associated with increased risk of falls, 
loss of independence, mobility issues, and mortality.  Evidence suggests some of the risk 
factors for sarcopenia, such as sedentary lifestyle, low physical activity, bedrest, chronic 
disease, certain drug treatments, malnutrition, anabolic resistance, intermuscular adipose 
tissue infiltration, and decreased neuromuscular activation, are modifiable.  Also, both 
the prevention and treatment of sarcopenia call for prescription of physical activity.  
Therefore, the overall interest of this dissertation was to investigate several of these 
modifiable risk factors in a group of older adults.  Our purposes were to explore the 
cross-sectional (study 1) and longitudinal relationship (study 3) of physical activity and 
sarcopenia in older adults and to develop a functional Get-Up test for older adults that 
may be used as a screening tool (study 2) to identify individuals at higher risk of 
developing sarcopenia. 
The goal of the first study was to investigate the cross-sectional association 
between physical activity, sedentary time, cardiorespiratory fitness, and muscular 
strength and sarcopenia in older adults.  A large sample of 304 adults aged 65 years or 
older completed surveys and physical measurements of a wide range of health-related 
variables.  We found that about 10% of the individuals had sarcopenia and that physical 
activity, sedentary time, cardiorespiratory fitness, and muscular strength were associated 
with sarcopenia, even when controlling for additional factors relating to the disease.   
xvi 
The second study established the reliability and validity of a new Get-Up test of 
whole-body fitness, function, and strength.  We found that the test had adequate 
reliability across trials and over time.  The validity of the test was established in a variety 
of ways.  It was moderately to strongly correlated with existing methods for measurement 
of fitness, function, and strength for older adults.  In a linear regression model, a 
combination of grip strength (strength), short physical performance battery (function), 
and a 400-meter walk (fitness) predicted a significant amount of the variance in the Get-
up Test.  Slow completion of our new Get-Up test was associated with higher prevalence 
of sarcopenia compared to those who completed test more quickly. 
The third study explored the changes in physical activity, sedentary time, 
cardiorespiratory fitness, and muscular strength with changes in sarcopenia components, 
as well as with the hazard of developing sarcopenia over the follow-up period.  Two-
hundred and forty-six participants completed the follow-up measurements and did not 
have sarcopenia at baseline.  Incidence of sarcopenia was found to be 9% over an average 
of 0.9 years of follow-up.  The strongest predictor of developing sarcopenia was slower 
completion time on a fitness test compared with their baseline performance.  Due to a 
small number of cases of sarcopenia observed at follow-up, further research is needed to 
explore the relationship between physical activity, sedentary time, and strength with 
incident sarcopenia. 
This dissertation advances our understanding about the relationship between key 
modifiable variables and sarcopenia in older adults.  Most physical activity and 
sarcopenia studies have not explored the impact of sedentary time, cardiorespiratory 
fitness, or strength and have used self-reported physical activity, which causes 
xvii 
measurement errors, and underestimates the true benefits of physical activity by over-
reporting.  Often these studies failed to follow an established definition of sarcopenia or 
use an accurate measurement device for establishing low muscle mass.  We believe these 
studies fill an important gap in our knowledge of the effects of physical activity on 
sarcopenia by adding more reliable data from stronger assessments of physical activity, 
sedentary time, cardiorespiratory fitness, muscular strength, and sarcopenia, as well as 
offering a valid and reliable potential screening tool, Get-Up test, that is appropriate for 
an older adult population.  
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CHAPTER 1.    INTRODUCTION 
Skeletal muscle serves three major functions: maintenance of posture and locomotion, 
storage of protein and amino acids, and heat production (1), but muscle mass, along with 
strength and function, is lost with age (2).  This characteristic loss in muscle mass, muscle 
strength and physical function is typical of the geriatric syndrome sarcopenia.  In a review by 
Mitchell and colleagues (3), the median annual muscle mass loss in adults over 75 years old 
from longitudinal studies was 0.8-0.9% in men and 0.6-0.7% in women, but a 
disproportionate amount of strength was observed corresponding to 3.0-4.0% / year in men 
and 2.5-5.0% / year in women.  These age-associated changes have serious consequences on 
quality of life, activities of daily living, risk of falls and fractures, mobility, disability, 
hospitalization, institutionalization, and mortality (4–9).  The cost of health care for 
sarcopenia was estimated to be over $18.5 billion dollars (in dollar value from 2000) in the 
USA alone (10). 
Sarcopenia comes from the Greek roots “sarcos” referring to flesh and “penia”, a lack 
of, giving the meaning a poverty of flesh.  This initial definition has gradually moved from 
low muscle mass to loss of muscle mass, muscular strength, and physical function.  The 
prevalence is reported to be between 3-60% in older American men and women (10–19).   
Risk factors for sarcopenia include sedentary lifestyle, low physical activity, bedrest, 
chronic disease, certain drug treatments, malnutrition, anabolic resistance, intermuscular 
adipose tissue infiltration, and decreased neuromuscular activation (7,20–23).  But physical 
activity, specifically resistance training, and diet play an important role in both prevention 
and treatment of sarcopenia (16,24).   
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CHAPTER 2.    LITERATURE REVIEW 
2.1 Sarcopenia 
2.1.1 Aging and Sarcopenia 
Skeletal muscle is a dynamic and plastic tissue, which contributes approximately 50% 
of total body weight and 50-75% of all body protein(1).  Three major functions are served by 
skeletal muscle: maintenance of posture and locomotion, storage of protein and amino acids, 
and heat production (2).  Muscle mass is generally the result of total protein synthesis and 
degradation over time, which are influenced by nutritional status, hormonal balance, physical 
activity, injury, disease and other factors (1).  This complicated relationship is partially 
depicted in Figure 1 (2). 
 
Figure 2-1. Factors influencing protein synthesis and breakdown resulting in preservation or 
loss of muscle functional reserve: Figure from Goldspink study (2). 
Functional reserve capacities of skeletal muscle decline with age (2).  This reserve 
capacity can extend the time of independent living and delay disability (3).  Functional 
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reserve represents the additional ability above the minimum level to complete activities of 
daily living.  Figure 2 illustrates the effect of trauma, for example a surgery or fall, on 
functional reserve.  The y-axis represents the capacity of the individual to do tasks.  The x-
axis represents age in years.  As capacity drops, heavy tasks and later light tasks (various 
activities of daily living; ADLs), become too difficult for the individual to accomplish.  In 
this hypothetical illustration, the effect of the trauma was a reduction in ten years of 
independent living and therefore described as “instant aging”.  Loss of skeletal muscle, 
strength and functional capacity in older adults as a result of bedrest is very likely to result in 
an independent individual with a small functional reserve becoming nonambulatory or 
dependent (4). 
 
Figure 2-2. Effect of a trauma on functional reserve: Figure from Hayes study (3). 
Aging has been associated with increasing levels of inactivity and decreased vigorous 
activity in older people (Figure 3), as reported in the ALSA study (5).  Other factors which 
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were associated with lower likelihood of being persistently active were female sex, ever 
having smoked, long-standing illness, arthritis, obesity and depressive symptoms (5).   
 
Figure 2-3. Pattern in self-reported frequency of physical inactivity / activity over 10 years, 
measured every 2 years in English females and males ≥ 50 years old at baseline: Figure from 
Smith study (5). 
A review of muscle mass and strength loss with aging by Mitchell et al. (6)reported a 
median muscle mass loss from cross-sectional studies of 0.47% / year in men and 0.37% in 
women over 65, whereas longitudinal studies showed muscle mass loss of 0.80-0.98% / year 
in men and 0.64-0.70% in women over 75 years old.  But a disproportionate loss in strength 
was observed corresponding to 3-4% / year in those men and 2.5-5% per year in those 
women over 75 years old (6).  Age-related lowering of myosin heavy chain (MHC) type IIa 
and IIx has been observed (7).   Age-related loss of muscle mass affects older individuals 
through reduction in ability to complete activities of daily living due to decreased total 
strength and exercise capacity (8).  Aging is associated with reduced insulin-like growth 
factor I signaling, elevated amounts of circulating cytokines increased cell oxidative stress, 
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and loss of spinal motor neurons due to apoptosis, which is paralleled by a reduction in 
muscle fiber number and size that impairs performance and reduces functional capacity of 
everyday tasks (9).  An etiological model of sarcopenia can be seen in Figure 4. 
 
Figure 2-4. Etiological framework for the development of sarcopenia: Figure from Morley 
study (10). 
2.1.2 Definition and Prevalence of Sarcopenia 
The term sarcopenia was first coined by Irwin Rosenberg with the purpose of giving a 
name to a condition that needed greater attention (11).  The idea reaches back into antiquity, 
as early as Aristotle, also Shakespeare and other authors, who commented about gradual loss 
of muscle as a factor of age (6).  Simply, the word sarcopenia is derived from the Greek 
"sarcos" referring to flesh and "penia", a lack of, which gives the meaning a poverty of flesh.  
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Initially, the definition required only low muscle mass to diagnose sarcopenia.  Baumgartner 
et al. (12) published the first objective definition using dual-energy X-ray absorptiometry 
(DXA) to measure absolute muscle mass divided by height squared.  Being two standard 
deviations (SD) below a sex-specific reference population (18-40 years old) defined the 
condition (12).  Ian Janssen also proposed a definition in 2002 using bioelectrical impedance 
analysis (BIA) from total muscle mass divided by total mass or skeletal muscle index (SMI) 
(13).  Being 1-2 SDs below sex-specific mean of young adults would be classified as Class I 
sarcopenia and >2 SDs was considered Class 2 sarcopenia.   
Some of the first publications dealing with sarcopenia addressed the issue that mass 
and strength do not have a linear relationship (14), therefore another term should be used 
such as dynapenia or a more complete definition of sarcopenia which included other relevant 
variables be defined.  This issue led to further development of sarcopenia definitions, which 
have been published over the past several years and now incorporate physical function and 
muscle strength as criteria in the definition of sarcopenia.   
The European Working Group on Sarcopenia in Older People (EWGSOP) definition, 
confirmed at a meeting with the European Geriatric Medical Society, the European Society 
for Clinical Nutrition and Metabolism, and the International Association of Gerontology and 
Geriatrics, establish a definition, variables, recommended measurement tools and cut-points 
of sarcopenia (15).   The EWGSOP defined sarcopenia as a syndrome characterized by a 
progressive and generalized loss of skeletal muscle mass and strength with a risk of adverse 
outcomes such as physical disability, poor quality of life and death.  Criteria consist of low 
muscle mass along with either low muscle strength or low physical function.  Despite the fact 
that the term dynapenia, which is an age-associated loss of muscle strength and function, 
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more accurately describes the syndrome, the EWGSOP stated that a change in the established 
term of sarcopenia may lead to further confusion.   
When ageing is the only clear cause then the condition is called primary sarcopenia is 
considered, whereas secondary sarcopenia would be the result of another condition (activity-
related, disease-related, or nutrition-related).  Presarcopenia is the existence of low muscle 
mass, sarcopenia the same plus either low muscle strength or low performance and severe 
sarcopenia the presence of all three (15).   
Muscle mass can be measured using computed tomography (CT scan), magnetic 
resonance imaging (MRI), DXA or Bioimpedance analysis (BIA).  Muscle strength can be 
measured using isometric handgrip strength, knee flexion or peak expiratory flow.  Finally, 
physical function can be measured using the Short Physical Performance Battery (SPPB), 
which evaluates balance, gait, strength and endurance by various tests (holding three foot 
positions [side-by-side, semi-tandem and tandem], time to walk 8ft, and time to rise from a 
chair and return to a seated position five times), usual gait speed, timed-get-up-and-go tests 
(time needed to stand up from a chair, walk a short distance, turn around, return and sit down 
again) and stair climb power test (power calculated from the time to ascend 10 stairs) (15).   
Cut-points should be based on normative (healthy young adult) populations at two 
SDs below the mean reference value.  For example, appendicular skeletal muscle mass 
(ASM) normalized by height squared results in a variable Baumgartner and colleagues (12) 
also called skeletal muscle mass index (SMI), which can be measured by DXA or BIA.  
Generally, the cut-point for muscle mass when measured by DXA is SMI (appendicular 
skeletal muscle mass/height2) of < 7.26kg/m2 for men and of 5.5kg/m2 for women.  Grip 
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strength (GS) cut-points can be absolute (<30kg for men and <20kg for women) or relative to 
BMI (Men: if BMI ≤ 24, then GS ≤ 29 kg, BMI 24.1–26, then GS ≤ 30 kg, BMI 26.1–28, 
then GS ≤ 30 kg, BMI > 28, then GS ≤ 32 kg; Women: if BMI ≤ 23, then GS ≤ 17 kg, BMI 
23.1–26, then GS ≤ 17.3 kg, BMI 26.1–29, then GS ≤ 18 kg, BMI > 29, then GS ≤ 21 kg).  
The cut-point for physical function should be gait speed of <0.8m/s, but if SPPB is used the 
cut-point is ≤ 8 (out of 12 maximum) (15).  
In practical terms, EWGSOP recommends using a flow chart to diagnose sarcopenia 
(see Figure 5).  For research following EWGSOP, many studies use DXA or BIA for muscle 
mass, handgrip strength for muscle strength, and usual gait speed for physical function to 
identify sarcopenia.   
 
Figure 2-5. EWGSOP algorithm for diagnosis of sarcopenia in older adults: Figure from 
Cruz-Jentoft study (15). 
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The Society of Sarcopenia, Cachexia and Wasting Disorders (SCWD) calls the 
syndrome in question sarcopenia, i.e. reduced muscle mass, with limited mobility (10). 
Criteria are walking speed less than 1m/s in a 400m or 6-min walk test and lean appendicular 
mass corrected for height (ASM/h2) less than 2 SD below the mean of healthy persons 
between 20-30 years of age for the same ethnic group.  But mobility impairment should not 
be the direct effect of specific disease.  An increase of 50m in the 6-min walk test or an 
increase in usual gait speed of 0.1m/s would be considered a clinically significant 
improvement in mobility (10). 
The Asian Working Group for Sarcopenia (AWGS) considers sarcopenia a geriatric 
syndrome, characterized by age-related decline in skeletal muscle plus low muscle strength 
and/or physical function (16).  This follows from the EWGOP definition but did set a 
minimum age of 60 or 65 years based on the definition of elderly in the country of interest.  
The current recommendation is use of DXA or BIA for muscle mass, although CT and MRI 
are also acceptable, grip strength for muscle strength and usual gait speed for physical 
function.  The cut-points are 7.0kg/m2 DXA/BIA for men, 5.4kg/m2 DXA or 5.7kg/m2 BIA 
for women or alternatively the lowest quintile, grip strength <26kg for men and <18kg for 
women or alternatively the lowest quintile, and usual gait speed <0.8m/s.  The alternative use 
of lowest quintile is a result of a lack of studies to establish strong cut-points for muscle mass 
and grip strength in Asian populations.     
The International Working Group on Sarcopenia (IWGS) defined sarcopenia as the 
age-associated loss of skeletal muscle mass and physical function and considered it a 
complex syndrome (17).  Cut-points for physical function is a gait speed <1.0m/s and low 
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muscle mass (<20th percentile from healthy young adults) of ALM/ht2 of ≤7.23 kg/m2 for 
men and 5.67 kg/m2 for women. 
The Foundation for the National Institutes of Health (FNIH) organized private and 
public organizations (academia, professional organizations, government and private sector) 
with relevant datasets to collaborate in identifying clinically relevant weakness and low lean 
mass (18).  Nine datasets from large cohorts were used to evaluate cut-points.  The 
recommended cut-points for diagnosis are physical function of <0.8m/s for usual gait speed, 
low grip strength of <26kg for men and <16kg for women (alternatively grip strength/BMI of 
<1.0 for men and <0.56 for women), and appendicular lean mass adjusted for BMI 
(ALM/BMI) of <0.789 for men and 0.512 for women (alternatively ALM of <19.75kg for 
men and <15.02kg for women).  In a follow-up publication, the new operational definition 
was compared with IWGS and EWGSOP definitions and was shown to have much lower 
prevalence (FNIH prevalence 1.3/2.3%, IWGS 5.1/11.8%, and EWGSOP 5.3/13.3% for 
males and females, respectively), possibly due to ALM being normalized by BMI instead of 
height, and lower cut-points for grip strength (19). 
Between 1989 and 2004, the reported prevalence of sarcopenia varied from 3-60% in 
women and men 60 years and older in samples from the USA (12,13,20–27).  In these 
studies, sarcopenia was defined as low muscle mass compared to a healthy, young reference 
group (≤2SD below the appendicular skeletal muscle mass / ht2) (17).  The wide range of 
prevalence can be partially explained by the difference in equipment being used to measure 
muscle mass (DXA or BIA) and the reference group that was selected (Rosetta study, 
NHANES III, Health Aging and Body Composition baseline cohort, and Cardiovascular 
Health Study). 
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Since the late 2000’s, many international groups have established their own 
definition, therefore, the definition (IWGS, EWGSOP, AWGS, FNIH, ASCW and 
ESPENSIG), equipment used to measure the variables (ie DXA vs. BIA) and variation 
among ethnic groups has led to a broad range of reported prevalence (28).  Differences 
between ethnicities have led use of ethnic-specific reference groups (22,29,30).   
2.1.3 Detrimental Effects of Sarcopenia 
Sarcopenia as a condition threatens the ability of an individual to live independently.  
Functional reserve can be slowly worn away with aging or drop suddenly with injury, illness, 
hospitalization or institutionalization.  Health care costs alone, calculated in dollar value from 
2000, were estimated to total over $18.5 billion ($10.8 billion for men, $7.7 billion for 
women), which accounted for 1.5% of the total annual health care (31).  This would cost 
sarcopenic men and women an extra $860 and $933 per year, respectively.  Janssen and 
colleagues argue that even a 10% reduction in prevalence of this modifiable economic 
burden would save $1.1 billion per year in U.S. healthcare costs.  The risk of complications, 
such as infections, pressure ulcers, loss of autonomy, institutionalization, poor quality of life, 
as well as for mortality, are also higher for hospitalized patients with sarcopenia (32). 
A loss of muscle mass will reduce the maximum volume of oxygen update (VO2
max), 
but age-related decrease in mitochondrial protein and myosin heavy chain synthesis rates 
have also been observed, which may explain some of features of sarcopenia (33).    Increased 
age is also associated with anabolic resistance, increased sedentary lifestyle, higher body fat, 
increases in inflammation, decrease in muscle quality (intramuscular fat infiltration) and 
poly-medication (34).  Kwan (35) argued that the detrimental effects of age on muscle motor 
neurons may account for the loss in strength observed in older adults.  Muscle is influenced 
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by its environment which has many positive and negative inputs, for example low vitamin D 
status and inflammatory conditions diminish muscle but physical activity and protein intake 
stimulate muscle (34). See Figure 6 for framework of the environmental impact on muscle 
tissue. 
 
Figure 2-6. Environmental factors affecting muscle tissue status: Figure from Rizzoli study 
(34). 
Mobility disorders, increased risk of falls and fractures, impaired ability to perform 
activities of daily living, disabilities, loss of independence and increased risk of death are 
associated with the impaired health of a sarcopenic individual (15).  Rizzoli et al. (34) argue 
that the reduction in muscle mass and decrease in physical function which defines sarcopenia 
is associated with gradual decline in quality of life (measured by the short form health 
survey, SF-36).   
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A four-year follow-up of community-dwelling men and women over 71 years of age 
or older showed that lower SPPB scores were associated with significant, gradual increase in 
the frequency of disability at follow-up, and after adjustment for age, sex and chronic disease 
those with the lowest scores were 4.2-4.9 times as likely to have disability at follow-up 
compared with those with the highest scores (36).  Cooper et al. (37) reported that physical 
functioning was predictive of likelihood of fractures, cognitive outcomes, cardiovascular 
disease, hospitalization and institutionalization in older community-dwelling populations.  
Lauretani et al. (38)reported in their cohort (inCHIANTI) of over 1,000 men and women 
from age 20 to 102 years old observing considerable reduction in isometric muscle strength 
and muscle power with age, which was subsequently associated with poor mobility (gait 
speed less than 0.8m/s and inability to walk 1km).   
2.2 Physical Activity and Sarcopenia 
2.2.1 Physical Activity Type and Sarcopenia 
Four months of moderate aerobic endurance training in older adults resulted in 
improved skeletal muscle function and other variables (increase in peak oxygen uptake, 
activity of muscle mitochondrial enzymes, mRNA levels of mitochondrial genes, GLUT4 
mRNA and protein, and reduced abdominal fat and plasma triglycerides) similar to younger 
adults, with the exception of insulin sensitivity which did not improve in older adults (39).  
Although, another study with higher intensity aerobic activity did show improvements in 
insulin sensitivity in older adults (40).   Absence of aerobic training over time, as seen in a 
sedentary older adult, may result in downregulation of oxidative metabolism, glycolysis, and 
amino acid metabolism and upregulation of branch chain amino acid degradation and redox 
homeostasis pathways compared to younger sedentary individuals (41).  Those changes were 
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not observed in older endurance trained adults.  Highly active (several times per week) 
individuals compared to low active (once per month or less) individuals had increased odds 
of 1.86 (1.24-2.79) of being nondisabled prior to death in very old age (42). 
Resistance training may provide protection from the detrimental effects of bedrest.  
The effect of 14 days of bedrest on the control group was a 46% reduction in muscle protein 
synthesis in the vastus lateralis.  This effect was not present in the exercise group that 
performed three sets of 10-12 repetitions of resistance training every other day during bed 
rest (43).  A Cochrane Systematic Review of progressive resistance training (PRT) on 
physical function revealed that compared to control, PRT groups improved physical function 
(gait speed, timed "Up-and-go",  and repeated chair stands) with a small to moderate effect 
size (44).  Also, higher intensity PRT was shown to have a greater effect on strength than 
lower intensity training.  The authors concluded that 2-3 times per week of PRT can improve 
physical function (reduce physical disability, functional limitation and muscle weakness) in 
older adults. Loss in appendicular skeletal muscle mass in older men, regardless of age, BMI, 
lifestyle, physical function, health status, body composition and blood measures, was 
predictive of all-cause mortality (45), but 12-week progressive resistance training (PRT) in 
the oldest old has been shown to produce significantly increased strength, hypertrophy of 
type 2a fibers, and 10% increase in lean cross-sectional area.  These effects were of similar 
magnitude to gains observed in young subjects (46).  Improvement in strength from PRT has 
been observed even into the tenth decade of life, as well as muscle size and functional 
mobility (47).   
In the US population, it is estimated that only 27% participate in leisure-time 
resistance exercise, and for those over the age of 50, the rate is substantially lower (48).  
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Strength training, though, elicits effective countermeasures even in the oldest old such as 
muscle hypertrophy and substantial changes in neuromuscular function, which result in 
increased functional capacity to do activities of daily living (9).    
Goodpaster and colleagues (49) conducted a randomized controlled trial with 42 older 
adults (mean age 77.1±1.0, 11 male).  The intervention group completed a 1-year physical 
activity intervention consisting of aerobic, strength, flexibility and balance training, whereas 
the control group attended health education sessions.  The control group lost muscle power 
and increased intermuscular adipose tissue, whereas the intervention group did not.  Three 
days per week of both endurance and resistance training on a regular basis was, therefore, 
recommended for adults and older frail people to maintain and increase muscle mass and 
strength and improve maximum aerobic power by the authors (50).   
2.2.2 Sedentary Behavior and Sarcopenia 
Some major risk factors for sarcopenia include bed rest and sedentary lifestyle (51).  
In a study looking at physical inactivity, individuals who were highly ambulatory (walking 
>10,000 steps per day) but otherwise exercised very little (<2 h/wk) were asked to reduce 
steps per day to under 1500.  The results of 2 weeks of low movement were reduced insulin 
signaling to Akt in skeletal muscle, reduced VO2
max of 7% and significantly lower lean mass 
in the legs of 2.8% (0.5kg) (52).  In older adults, muscle loss as the result of bedrest is greater 
when it is due to an incident (illness, injury, etc.) (4).  Decreased muscle activity may 
partially explain the changes in protein metabolism during bedrest or immobilization (4).  
Older adults lost a greater amount of lean tissue after only ten days bedrest than young 
individuals after 28 days (53). 
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2.2.3 Diet and Sarcopenia 
The importance of adequate nutrition in older adults should not be understated.  
Research shows that approximately 15-38% of men and 27-41% of women fail to meet the 
dietary guidelines of 0.8g/kg/day of dietary protein (54).  Even older adult subjects provided 
a controlled diet (0.8g/kg/day dietary protein) for 14 weeks showed decreased mid-thigh 
muscle area, which was correlated with the decrease in urinary nitrogen excretion, suggesting 
that 0.8g/kg/day may be inadequate to fulfill the metabolic and physiologic needs of older 
adults (55).  Recent  recommendations from the study group on meeting protein needs of 
older people (PROT-AGE) state that older adults should consume at least 1.0-1.2g/kg/day, 
but individuals who participate in physical activity and exercise should have >1.2g/kg/day.  
Additionally, those who have acute or chronic disease need even more (1.2-1.5g/kg/day) 
(Bauer et al., 2013).  
 
Figure 2-7. Factors affecting lower protein intake in older adults: Figure from Deutz study 
(56). 
Similar recommendations for daily dietary protein intake were published by the 
European Society for Clinical Nutrition and Metabolism (ESPEN), which prescribed 1.0-1.2 
g/kg/day for healthy older adults, 1.2-1.5 g/kg/day for malnourished individuals or those at 
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risk for malnutrition and also encourage daily physical activity or exercise including 
resistance and aerobic training for all older adults (56).  Factors influencing lower protein 
intake can be seen in Figure 7.   
Older adults may need higher protein intake for a variety of reasons.  See Figure 8, 
which illustrates the many issues that drive daily intake values higher for older adults.  Older 
adults may need to consume a larger amount of dietary protein to gain the maximal muscle 
protein synthetic response, which may be due to anabolic resistance (57).  Anabolic 
resistance is illustrated in Figure 9.     
 
Figure 2-8. Factors affecting higher protein intake needs for older adults: Figure from Duetz 
study (56). 
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Figure 2-9. Secondary factors influence the ingestion of a protein meal that interfere with 
stimulation of protein synthesis: Figure from Burd study (57). 
2.3 Muscular Strength and Sarcopenia 
2.3.1 Assessment of Muscular Strength 
Muscular strength is the capacity of a muscle to produce the tension necessary for 
maintaining posture, initiating movement, or controlling movement during conditions of 
loading on the musculoskeletal system (58).  Accurate assessment of muscular strength is 
critical for evaluating changes in physical function, especially in response to various stimuli 
(aging, physical activity, sedentary behavior, and diet).  A variety of tools are commonly 
used to assess strength.  They may be isotonic, isometric or isokinetic in nature.  Isotonic 
refers to a constant tension while the muscle length changes.  An example of an isotonic 
strength measure may be a one repetition maximum protocol with free-weights or a weight-
machine.  Isometric refers to the contraction of the muscle without change in the joint angle 
or muscle length.  A dynomanometer used to measure grip strength allows the amount of 
force generated to be measured while the distance between the fingers and the hand does not 
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change.  Isokinetic is allowing for a constant velocity throughout the contraction.  The 
Biodex is a machine that allows constant speed around a fixed axis for a certain range of 
motion allowing variable amounts of force to be applied against it. 
A number of principles should be taken into account when performing strength tests.  
A proper warm-up should increase muscle temperature, activate intermuscular energy 
sources, activate hormonal resources, alert the nervous system and decrease core body 
temperature (58).  The test position of the measurement should be comfortable to the 
participant, stabilize the body, maintain the appropriate joint angle and isolate the muscle or 
muscle group of interest (58,59).  When possible, multiple measures of strength should be 
recorded for baseline and attention should be given to standardization of the measurement to 
minimize the influence of extraneous factors (58).   
Peak torque (PT) is recommended in research and clinical settings for measurement 
of muscular strength using isokinetic equipment and is the gold standard and reference point 
in all isokinetic measurements (59).  At speeds of 0 to 60 degrees per second, which allow 
both type I and II fibers to be maximally activated, PT stays nearly unchanged (59).  Figure 
10 shows PT at specific angular velocities illustrating that PT is consistent at slower 
velocities.  Figure 11 depicts an example of the torque-displacement curve.    
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Figure 2-10. Peak torque at specific angular velocities (degree/s) in knee extension and 
flexion using an isokinetic dynamometer: Figure from Kannus study (59). 
 
Figure 2-11. Typical isokinetic torque-displacement curve from a male subject during knee 
flexion: Figure from Kannus study (59). PT, peak torque; PTA, peak torque angle; AST, 
angle-specific torque; TAE, torque acceleration energy. 
Another clinically relevant measure of strength is the 1 repetition maximum (1RM), 
the maximal amount of weight that is able to be moved only once through the range of 
motion of a joint (1).  Given the learning effect, reliability of the test will increase with 
practice or familiarization of the subject with the test (1).   
2.3.2 Dynopenia and Sarcopenia 
Muscular strength is modifiable, even in older adults, and resistance exercise is 
effective for improving strength (60).  The increased capacity to generate force can be 
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attributed to muscle hypertrophy, which increases as a result of protein synthesis and the 
addition of myofilaments, myofibrils, and sarcomeres, possibly due to activation and fusion 
of satellite cells, as well as the activation of signaling pathways (insulin-like growth factor 1 
and myostatin), gene-activation, and dietary protein intake (1). 
Muscular strength is not perfectly correlated with the size of the muscle which 
suggests that other factors also contribute to force production (1).  Some longitudinal work 
shows that a loss in cross-sectional area of muscle (loss in muscle mass) was a major 
contributor to loss in strength over a 12-year follow-up (61), while other data show great 
variability across individuals (See figure 12 for histogram of annualized changes in muscle 
strength) (62).   
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Figure 2-12. Histogram of annualized changes from 10 year follow-up in muscle strength 
for four muscle groups by sex: Figure from Hughes study (62).  Percentage represents the 
portion of the total sample that did not decrease strength from baseline to follow-up. 
A recent review by Clark & Manini (63) presented numerous potential influences on 
dynapenia in older adults, such as impairments in neural (central) activation, reduction in 
muscle quality, and contractile quality.  They created a theoretical biological framework of 
mechanisms contributing to dynapenia (See Figure 13).  Healthy and mobility-limited older 
adults followed over a 3-year interval lost significant amounts of strength which was 
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accounted for by declines in neuromuscular activation and had little to do with muscle size 
and strength (64).  Furthermore, the authors determined that intermuscular adipose tissue 
infiltration had a significant and inverse association with contractile velocity and power 
output (64).  Finally, neuromuscular activation deficits may precede losses in muscle size and 
strength (64).   
 
Figure 2-13. Proposed biological mechanisms which contribute to dynapenia in older 
adults from Clark study (63). 
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CHAPTER 3.    PHYSICAL ACTIVITY AND SARCOPENIA IN OLDER ADULTS 
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Nathan F. Meier1, Duck-Chul Lee1 
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3.1 Abstract 
Purpose: to quantify the association between objectively measured physical activity 
(PA), sedentary time (SED), cardiorespiratory fitness (CRF), and strength (STR) with 
sarcopenia in a large group of community-dwelling older adults using a standard definition of 
sarcopenia. 
Methods: This cross-sectional study examined a large group of older adults (n=304) 
who provided a broad range of health, lifestyle, and socioeconomic variables.  PA was 
assessed using a pedometer worn for 7 days.  SED was assessed using a survey.  CRF was 
assessed by performance on a 400-meter walk test.  Strength (STR) was assessed by one-
repetition maximum chest and leg press.  The European Working Group on Sarcopenia in 
Older People (EWGSOP) definition of low appendicular lean mass (ALM) using DXA, and 
either low handgrip strength or slow gait speed, defined 10.9% (n=33) as sarcopenic.   
Results: PA, CRF, and STR were significantly associated with sarcopenia 
components (muscle mass, muscle strength, and muscle function).  The upper two thirds of 
CRF had significantly lower odds of having sarcopenia, whereas the strongest third of STR 
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was associated with lower odds of sarcopenia.  All exposure variables had significant odds 
ratios associated with at least one component of sarcopenia.  Joint analyses indicated 
additional benefit may be gained from being both active (≥5,000 daily steps) and fit (top two 
thirds), active and strong (top two thirds), and fit and strong.  
Conclusion: Overall, objectively measured PA, CRF, and STR, as well as self-
reported SED, are associated with sarcopenia and its components.  Therefore, older adults 
who are physically active, maintain higher levels of cardiorespiratory fitness, upper and 
lower body strength, and avoid sedentary time may have significantly lower odds of 
sarcopenia. 
3.2 Introduction 
Many older adults are unaware of the benefits of physical activity (PA) and often 
consider physical activity unnecessary or even harmful (1).  Quite the opposite is true.  If 
inactivity was eliminated, worldwide life expectancy would rise on average by 0.7 years and 
0.8 years in the USA, demonstrating inactivity is as detrimental to health as established risk 
factors such as obesity and smoking (2).  The specific effect of getting inactive people to 
become physically active would add 1.3-3.7 years to their life (3,4).   
Older adults are less active and suffer from more chronic diseases than younger 
people. One common disease is the age-related reduction of muscle mass, strength, and 
function, also known as sarcopenia.  It is also comorbid with other diseases, such as obesity, 
osteoporosis, and type II diabetes (5), as well as elevated risk of falls, decreased quality of 
life, loss of independence, and mortality (6). Although its causes are not fully understood, 
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inactivity, changes in hormonal levels, inflammation, and altered neuronal activity all 
contribute to sarcopenia (7).  
Prevalence rates of sarcopenia vary due to lack of a universal definition (8) and 
measurement devices used in diagnosis. 1-29% and 10-33% in community-dwelling and 
dependent-living older adults, respectively, are reported to have sarcopenia (9). Sarcopenia 
incidence projected to grow 1.8-2.1% annually, resulting in a dramatic 8-12 million new 
cases in Europe alone over the next 30 years (10). A recent systematic review of 35 studies 
on community-dwelling adults over 60 years of age estimated 10% prevalence using the 
definitions from the European Working Group on Sarcopenia in Older People (EWGSOP) 
and Asian Working Group on Sarcopenia (AWGS) in for non-Asian and Asian populations, 
respectively (11).  Therefore, 10% prevalence may be more reliable due to consistent use of 
sarcopenia definition and ethnic population, but it is likely too conservative due to inclusion 
of only independent older adults. 
Sarcopenia carries a significant financial ($18.5 billion in US health care costs in 
2000) and social (decreased quality of life) burden (12).  According to the U.S. Census 
Bureau, by the year 2050 the number of individuals over 65 years old will double from 40 
million to 88.5 million, which is nearly 20% of the US population (13). Both prevention and 
treatment of sarcopenia consist of increased PA, specifically progressive resistance training, 
appropriate amounts of high quality dietary protein, and vitamin D supplementation, but 
currently pharmaceutical treatments have not been fully established (14). Given the 
relationship between modifiable risk factors and sarcopenia, further investigation into 
physical activity habits is needed, such as cross-sectional and longitudinal studies including 
objectively measured data.  
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A recent systematic review and meta-analysis of cross-sectional and cohort studies 
examined the relationship between PA and sarcopenia (15).  Overall, participants who were 
at least somewhat active had lower odds (OR (95% CI), 0.45 (0.37, 0.55)) of sarcopenia 
compared to inactive.  Each of the 17 cross-sectional studies assessed PA using self-report, 
and 12 of 17 studies used only low muscle mass to define sarcopenia instead of a 
standardized definition.  Therefore, further research should use objectively measured PA and 
accepted sarcopenia definitions. Consistent use of the EWGSOP definition in non-Asian 
populations (AWGS has identified racial differences in diagnosing sarcopenia) would 
improve synthesis of data that could be compared. 
A recent review of randomized controlled trials (16) that combine exercise 
intervention and dietary intervention provided mixed results on the efficacy of treatment due 
to a range of differences.  Differences included exercise adherence, type, dose, intensity, and 
duration, as well as type of supplement and dose, and finally the baseline functional and 
nutritional (especially lacking protein intake at baseline) status of the subjects.  These 
limitations allow important questions to remain unanswered, such as the effects of combined 
interventions in sarcopenic and frail populations, populations with nutrition deficiency, and 
populations at risk for malnutrition.  Baseline physical activity and nutritional status are very 
important in addressing these issues in the future. 
Existing data on physical activity and sarcopenia in older adults has been collected 
using predominantly self-reported measures, which tend to over-report physical activity and 
have lower accuracy due to recall limitations (17). The most common form of PA for older 
adults is walking (18). Therefore, the use of an objective measurement device that accurately 
captures ambulatory movement, such as a pedometer, will record most physical activity in an 
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older adult population. This study aims to quantify the association objectively measured PA, 
sedentary time, fitness, and strength with sarcopenia in a large group of community-dwelling 
older adults using a standard definition of sarcopenia from the EWGSOP. 
3.3 Methods 
Participants were recruited from a mid-west university town and surrounding 
communities through postings, advertisements, and informational talks in local organizations. 
Between October 2015 and May 2016, 304 older adults, ages 65 years and older, who 
planned to live in the area long-term, were recruited.  Complete inclusion and exclusion 
criteria are listed in Table 3.1.  Exclusion criteria were plans to be out of the area extensively, 
cancer treatment in the past five years, or other severe conditions that would interfere with or 
make exercise unsafe and/or difficult, for example major heart, psychological, degenerative, 
or physical impairments.   
Participants were part of an ongoing, longitudinal cohort called the Physical Activity 
and Aging Study (PAAS).  Individuals participated in a series of laboratory visits over the 
course of two weeks involving questionnaires, physical activity, body composition, fitness, 
physical function, and strength.  This study was approved by the Institutional Review Board 
(IRB 15-430) at Iowa State University.  Procedures were fully explained to all participants.  
Prior to participation, all individuals provided written informed consent.  See Figure 3-1 for 
Participant Flow. 
3.3.1 Basic Anthropometrics  
Height was measured using a standard stadiometer in centimeters.  Weight was 
measured with a digital scale (Cardinal Detecto 758C Digital Scale, Webb City, Mo, USA) in 
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kilograms.  Body mass index (BMI) was calculated as weight in kilograms divided by height 
in meters squared. Waist circumference was measured in a standing position at the level of 
the umbilicus using a measuring tape after exhalation.  Measurements were taken while 
participants wore scrubs with no shoes.   
3.3.2 Exposure Measures 
3.3.2.1 Physical activity (PA) 
Daily steps were measure using a widely-used, validated, and accelerometer-based 
pedometer from Omron (Model HJ-321, Illinois, USA) (19). The pedometer, worn at waist 
level, calculated total daily steps over the course of 7 days. Overall, 94.4% had complete 
data, 3.6% had 6 days of step data, and 2% had only 5 days.  Three categories were made 
based on published cut-points for older adults of <2,500 steps per day (low), ≥2,500-4,999 
(moderate), and ≥5,000 (high) (20). 
3.3.2.2 Sedentary time (SED) 
Sedentary time was assessed using a comprehensive survey recording weekly time 
spent on average in each of the four domains (occupational, household, leisure-time, and 
transportation) based on the Compendium of Physical Activities (21) and the International 
Physical Activity Questionnaire (22). Three categories were made based on cut-points for 
older adults of < 8 hours per day (low), ≥ 8 and < 11 (moderate), and ≥ 11 (high) (23–25).  
3.3.2.3 Fitness (CRF) 
The 400-meter walk test was the time required to walk 10 laps “as fast as possible” on 
a 20-meter long course.  Rests of up to 60 seconds while standing were permitted.  The test 
was conducted in a long hallway that is approximately five feet wide.  Cones marked the 
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ends of the course. The researcher told the participant the number of laps completed and 
remaining each round. Three categories (low, moderate, and high) were made based on 
tertiles of 400m walk time for the present sample.  Other existing references for fitness could 
not be applied to this sample, for instance none of the participants had the failed to complete 
the 400m walk test (26), and only two failed to complete the test at slower than 1.19m/s (27) 
which indicates high mortality risk and future mobility disability, respectively. 
3.3.2.4 Strength (STR) 
ACSM guidelines were followed to determine muscular strength from one repetition 
maximum (1RM) chest and leg press (28).  The participant was given three progressive 
warm-up sets each followed by a two-minute rest.  The 1RM was determined within four 
trials with rest periods of two minutes between trials.  The initial weight was selected to be 
within the individual’s perceived capacity, and then resistance was progressively increased 
until the subject could not complete the repetition throughout the whole range of motion.  
The final weight lifted successfully was considered the individual’s 1RM.  The 1RMs were 
normalized by body weight (1RM / body weight), standardized ((value–mean)/SD) by age 
(65-69, 70-79, ≥80) and sex-specific mean and SD, and divided into tertiles (low, moderate, 
and high) for analysis (29,30).   
3.3.3 Outcome Measures (Sarcopenia and its Components) 
3.3.3.1 Appendicular lean mass (ALM) (Muscle mass) 
The full body scan was performed on the Hologic Horizon W model DXA (Hologic 
Inc., Bedford, MA) and Apex Software (Version 5.5.3).  A trained technician performed the 
scan with the participant supine in the standard fashion and wearing scrubs.  Software 
automatically defined regions on the trunk and appendages, which were then adjusted 
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manually by one trained technician.  DXA software measured whole and regional body 
composition measures, including fat mass (FM), percentage body fat (%BF), fat-free mass 
(FFM), appendicular lean mass (ALM), bone mineral content, and bone mineral density.  The 
DXA machine was calibrated daily using the manufacturer-provided phantom spine segment.     
3.3.3.2 Physical performance (Muscle function) 
Usual gait speed was measured as part of the Short Physical Performance Battery 
(SPPB) (31), which is a series of tests (balance, 4m gait speed, and chair stand) that gives a 
composite score (range 0-12, with higher indicating better function).  The participant’s usual 
gait speed was measured over four meters.  Participants began walking at the start line and 
were instructed to walk through the finish line as not to decelerate early.  Walking aids were 
allowed if used in everyday life. Time to complete the 4m course was recorded.  
3.3.3.3 Handgrip strength (Muscle strength) 
Handgrip strength was measured using a digital dynamometer (Jamar Plus+, 
Lafayette Instrument, Lafayette, IN, USA).  The width of the device was adjusted to the size 
of the participant’s hand such that the middle phalanx rests on the inner handle (32).  
Participants sat and held their elbow joint at a right angle and gripped the dynamometer for 
two seconds using each hand with maximal effort.  The best of three trials with one-minute 
rest between trials was used (33). 
3.3.3.4 Sarcopenia definition 
Sarcopenia was defined following the European Working Group on Sarcopenia in 
Older People (EWGSOP) guidelines due to Caucasian population and frequent use in 
published literature.  Other definitions were calculated and reported in Table 3.3 and 3.4 (34–
40 
36).  Recent meta-analyses on sarcopenia have also used literature following the EWGSOP 
definitions for pooling (37,38). 
3.3.4 Covariates 
Sociodemographic, lifestyle, personal and family medical history, depressive 
symptoms (Geriatric Depression Scale) (39), and self-reported health (40) were collected 
using a comprehensive survey. This provided measures of income (<$12,000, $12,000-
24,999, $25,000-49,999, $50,000-74,999, $75,000-99,999, >$100,000), education 
(Elementary, Jr. High, High School, College, Graduate School), smoking status (current 
smoker, not current smoker), heavy alcohol consumption (yes, no), and major medical 
conditions (0-7) including heart attack, heart failure, heart arrhythmia, stroke, abnormal 
ECG, type 2 diabetes, and chronic obstructive pulmonary disease.  Heavy alcohol 
consumption was drinking >14 drinks per week for men and >7 drinks per week for females 
(41).  Total kilocalories per day and daily protein intake were calculated using data from a 3-
day diet record, which was entered into a nutrient analysis program (The Food Processor 
SQL version 10.14.1, ESHA Research, Salem OR). Of the 304 participants, 213 (70%) diet 
records had sufficient quality to be analyzed. Exclusion criteria for diet records included 
inadequate nutrient information, improper recording of weekday to weekend-day ratio, and 
ineligible handwriting. 
3.3.5 Statistical Analysis 
Continuous variables are displayed as mean±SD, and categorical variables as number 
(percentage).  Comparisons between sex and age group (sarcopenic and non-sarcopenic 
groups) was performed using t tests or ANOVA for continuous variables and using chi-
square tests or Fisher exact test for categorical variables, as appropriate.  Age- and sex-
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specific prevalence were calculated.  Multivariable linear regression examined the 
relationship between continuous PA (daily steps from pedometer), CRF (400m walk 
performance), STR (1RM chest and leg press), and SED (self-reported sitting time) with 
sarcopenia variables (muscle mass, function, and strength).  Model selection was based off of 
a review of published papers on physical activity and sarcopenia (15) and includes 
socioeconomic, lifestyle, health, and multiple exposures of interest.  Multivariable logistic 
regression was used to examine physical activity variables, potential clinical and functional 
risk factors, and the likelihood of having sarcopenia.  Statistical significance was set at 
p<0.05.  All statistical analyses were done using SAS for Windows version 9.4 (SAS 
Institute Inc., Cary, NC, USA). 
3.4 Results 
Overall, participants were 72.2±5.8 years of age, 60% were female, with a BMI of 
27±4.9.  They had SPPB scores of 11.4±1.1 and completed a 400-meter walk in 4.5±0.8 
minutes (1.5m/s).  Participants reported being physically active on the self-report survey but 
daily steps from 7-days of pedometer indicated ~5,000±2632 steps per day, which indicates 
that most are on the border between active and sedentary.  79% reported “Good”, “Very 
Good” or “Excellent” health, which corresponds with a similar percentage reporting zero 
comorbidities as defined above. 
The more physically active participants were younger, had better function and fitness 
(SPPB, Gait speed, 400m walk), reported less sedentary time and higher health-related 
quality of life, and had fewer comorbidities.  Sarcopenic participants were older, differed in 
body composition (weight, waist circumference, BMI, fat and fat free mass, ALM), 
consumed more daily protein, had lower strength, function and fitness (1RM, handgrip 
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strength, SPPB, Gait Speed, 400m Walk), and spent less time in resistance-type activities 
(see Table 3.2).   
Prevalence of sarcopenia ranged from 0.6% to 10.9% depending on the definition (see 
Table 3.4).  EWGSOP identified the most individuals and FNIHSP identified the least.  More 
females were sarcopenic than males. 
Sarcopenia variables were associated with the main variables of interest (see Table 
3.5).  A significant portion of the variance was explained in models for ALM and handgrip 
strength.  PA (daily steps from 7-day pedometer wearing), CRF (time to complete 400 meter 
walk), and STR (lbs from bench and leg press) all appear to be significantly associated with 
ALM, but in model 3 (fully adjusted) STR had the only significant association, despite only 
low to moderate correlation between SED (hours/day), PA, CRF, and STR (data not shown).  
Both CRF and STR were significantly associated with handgrip strength.  Only CRF was 
significantly associated with gait speed, although the total variance accounted for was low.  
This may be due to the fact that gait speed has a complex association with overall health, 
multiple organ systems and physical activity, as well as being a metric for vitality (42,43).   
The coefficients of the lifestyle variables were in the expected directions.  For PA, 
additional steps per day corresponds to an increase in ALM.  For CRF, one additional minute 
of time required to complete the 400m walk test resulted in a decrease in ALM, handgrip 
strength, and a slower gait speed or a decrease in meters per second walked.  For STR, a one-
unit increase in strength resulted in increased ALM, handgrip strength, and faster gait speed.   
Physical activity was associated with insignificant trend of lower odds of sarcopenia 
prevalence with OR (95% CI) of 0.58 (0.14-2.38) in high active group (>5,000 steps/day) 
43 
compared to the low active group (<2,500 steps/day) (see Table 3.6).  However, achieving 
more than 5,000 steps/day was significantly associated with reduced odds of having low 
muscle mass and slow gait speed indicating that being active was associated with higher 
muscle mass and faster gait speed (p-trend <0.05). 
Cardiorespiratory fitness was associated with a significantly lower prevalence of 
sarcopenia, low muscle mass, and low handgrip strength (see Table 3.7).  The moderate 
tertile of 400m walk test was associated with reduced prevalence of having sarcopenia (0.19 
(0.06, 0.57)) and low handgrip strength (0.28 (0.12, 0.63)).  The high tertile had reduced 
prevalence of sarcopenia (0.14 (0.04, 0.50)), low muscle mass (0.17 (0.06, 0.50)), and low 
handgrip strength (0.25 (0.09, 0.70)).  Overall, being fitter was associated with lower 
prevalence of sarcopenia, higher muscle mass, and higher handgrip strength (p-trend≤0.003).   
Sedentary time was not associated with sarcopenia (1.08 (0.37, 3.15)) (see Table 3.8).  
Reporting sedentary time less than 8 hours per day was associated with lower odds of having 
low muscle mass and had a significant linear relationship (p-trend = 0.02).   
Strength was associated with a significantly lower prevalence sarcopenia, low muscle 
mass, and low handgrip strength, but not low gait speed (see Table 3.9).  Being in the 
moderate tertile was associated with reduced odds of having low muscle mass (0.32 (0.13, 
0.77)) and low handgrip strength (0.31 (0.13, 0.70)).  Being in the high tertile was associated 
with lower prevalence of sarcopenia (0.07 (0.01, 0.35)), low muscle mass (0.12 (0.04, 0.31)), 
and low handgrip strength (0.07 (0.02, 0.25)).  Being stronger was significantly associated 
with having reduced prevalence of sarcopenia, higher muscle mass, and higher handgrip 
strength (p-trend≤0.001).  A sensitivity analysis using strength from chest and leg press 
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normalized by body weight without age- and sex-specific standardization revealed slightly 
stronger associations between strength and reduced odds of sarcopenia, low muscle mass, 
and low handgrip strength (see Table 3.10).  These associations were stronger due to higher 
number of cases in the reference groups for these analyses. 
Joint associations between predictor variables were conducted to compare the 
independent and additive effects of combinations of PA, SED, CRF, and STR variables (see 
Table 3.11) on odds of having sarcopenia.  These joint analyses have great potential public 
health implications to maximize the benefits of PA, reduce sitting time, and improve fitness 
and strength in relation to sarcopenia.  Being physically active and sedentary was associated 
with lower odds of having sarcopenia.  Being fit, regardless of physical activity level, 
resulted in lower odds of having sarcopenia. Being in the top two thirds of strength was 
associated with lower odds of having sarcopenia, but additional benefit was gained from also 
being physically active.  Being in the top two thirds of fitness was associated with lower odds 
of having sarcopenia, but also being sedentary seemed to confer additional benefit.  Being 
both strong and sedentary was associated with lower odds of having sarcopenia.  Finally, 
being in the top two thirds of either fitness or strength was associated with lower risk of 
having sarcopenia, but some additional benefit was seen for those in the top two thirds of 
both fitness and strength. 
Given the low number of cases of low gait speed observed (n=14), it is unlikely for 
significant associations to be revealed due to lower statistical power.  In general, adding diet 
variables relevant to sarcopenia (total kcals per day, daily protein intake) into the logistic 
regression models reduced the number of cases (9-22%) and significantly decreased the 
sample size (30%) because of the significant missing or insufficient data on diet (30%), This 
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resulted in smaller associations between exposure and outcome variables and wider 
confidence intervals (data not shown), although the trends of the results were generally 
similar.  Therefore, the final model did not include diet variables despite their clear 
importance in analyzing the data. 
3.5 Discussion 
In this study of community-dwelling older adults, the results indicate that physical 
activity (PA), sedentary time (SED), cardiorespiratory fitness (CRF), and strength (STR) 
were associated with sarcopenia or components of sarcopenia (low muscle mass, low grip 
strength, or slow gait speed). The 10.9% prevalence of sarcopenia observed was similar to 
data summarized in a recent review (11).  Therefore, older adults who are physically active, 
maintain higher levels of cardiorespiratory fitness, upper and lower body strength, and avoid 
sedentary time may have significantly lower odds of sarcopenia.  
Our results regarding the associations between PA and sarcopenia are consistent with 
earlier literature.  A recent review and meta-analysis indicated a consistent relationship 
between PA and sarcopenia in cross-sectional and cohort studies as well as lower odds of 
having sarcopenia in more active groups compared to less active groups (0.45 (0.37, 0.55)) 
(15).  Most studies lacked objectively measured PA, standard measurements of ALM like 
DXA, and failed to follow an established sarcopenia definition.  A recent study in older 
adults from England using accerometry-based PA indicated that a standard deviation (SD) 
increase in average acceleration reduced the risk of having sarcopenia (0.65 (0.43, 0.99)), but 
single SD increases in moderate to vigorous physical activity (MVPA) and non-sedentary 
time were not significant in the fully adjusted model including gender, age, height, weight-
for-height residual, smoking history, alcohol consumption, and social class as potential 
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confounders (0.67 (0.44, 1.01) & 0.70 (0.43, 1.13)) (44).  Objectively-measured PA was 
associated with severe sarcopenia even after adjusting for SED, although only mid-arm 
muscle circumference was used to identify low muscle mass instead of DXA (17). Over 71% 
of our sample failed to accumulate on average 5,000 steps per day, classifying them as 
sedentary.  Normative data indicates that healthy older adults accumulate >6,000 steps daily 
(20).   
Regarding the associations between SED and sarcopenia, stronger associations were 
present in other studies, whereas sitting less than 8 hours per day was associated with lower 
odds of low muscle mass (0.43 (0.19, 0.98)) in the present study.  Six of the nine regression 
models indicated that SED was a significant risk factor for older adults (15). Aggio and 
colleagues reported that additional sedentary time was associated with severe sarcopenia, 
although the relationship was no longer significant after adjusting for MVPA (17).   
The results exploring the association between CRF and sarcopenia indicate a strong 
relationship.  Being in the fastest two tertiles of the 400-meter walk test was significantly 
associated with sarcopenia (80-85% lower odds), low muscle mass, and low grip strength.  
Few other studies have explored this relationship.  One study found associations between 
components of fitness (balance, strength, flexibility, aerobic capacity) and sarcopenia, 
identified by low fat-free mass measured by bioelectrical impendance (45), and another 
found an association using a 3-minute step test for fitness and sarcopenia identified by low 
muscle mass only (46).   
No other studies were found exploring the relationship between STR and sarcopenia.  
Our results indicate a low prevalence of sarcopenia (93% lower odds) by being in the 
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strongest tertile, as well as a 68-78% lower odds of having low muscle mass and 69-93% 
lower odds of low grip strength by being in the top two strongest tertiles.   
Inactivity, indicated by low step counts, is a form of mild immobilization or disuse 
and occurs more often in older adult populations compared to younger adults (47).  Older 
adults subjected to four days of reduced steps failed to return to baseline values of dynamic 
strength, isometric strength, and rate of force development after a seven day recovery, but the 
young individuals showed a full recovery (48).  Another reduced ambulation study in older 
adults recorded a loss of 3.9% (0.4kg) reduction in leg lean mass, which is equivalent to a 
twice the typical annual loss in just two weeks (49).  Reduced steps and sedentary behavior 
appear to blunt the response to ingestion of dietary protein, leading to lower muscle protein 
synthesis and a net loss in muscle mass (47).  Due to its role in lipid oxidation and post-
prandial glucose disposal, maintenance of muscle mass is critical for metabolic health (47).  
Overall, physical inactivity in older adults is a primary cause of insulin resistance and 
progression of type 2 diabetes (50). 
 Several limitations should be acknowledged.  Overall, only 33 cases of sarcopenia 
were observed at baseline, of which the lowest cases came from low gait speed, therefore the 
associations with low gait speed were limited across all exposure variables.  Although, PA, 
CRF, and STR were objectively measured, SED was self-reported, therefore this 
measurement is subject to recall error and over/underestimation that the other variables were 
not.  Assessments were conducted across multiple seasons allowing for some variation due to 
climate that was not controlled.  The cross-sectional design allows exploration of the 
associations between variables, but causal links were not possible.  Finally, the sample 
48 
appeared to be quite healthy, possibly indicating a healthy responder bias, and came from a 
sample without ethnic diversity, therefore generalizability to the population may be limited.   
The study had various strengths.  This is one of the few studies that included 
objective measurement of exposure variables and a DXA-derived definition of sarcopenia.  
To our knowledge, this is the only study to explore all PA, SED, CRF, and STR and 
sarcopenia in the same study.  Finally, the full model included a comprehensive set of 
variables associated with sarcopenia, which is lacking in many cross-sectional studies. 
In conclusion, we have shown that objectively measured physical activity, 
cardiorespiratory fitness, and strength, as well as self-reported sedentary time, appear to be 
associated with sarcopenia and its components.  Therefore, older adults who are physically 
active, maintain higher levels of cardiorespiratory fitness, upper and lower body strength, and 
avoid sedentary time may have lower odds of sarcopenia prevalence. 
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3.7 Tables and Figures 
Table 3.1. Inclusion / Exclusion Criteria 
Inclusion Criteria 
 female or males 65 years old or older 
 BMI < 45 or weight < 350lbs (160kg) 
Exclusion Criteria 
 plans to move out of Ames in the near future 
 plans to be away >4 weeks in the next 12 months 
 arthritis or joint pain that would prevent participation in fitness testing (submaximal 
treadmill test and muscular strength tests) 
 mental or physical impairment leading to inability to exercise adequately 
(schizophrenia, hospitalization for depression, etc.) 
 any other condition that is life-threatening that can interfere with or be aggravated 
by exercise 
 unstable angina  
 uncontrolled cardiac dysrhythmias causing symptoms or hemodynamic 
compromise  
 symptomatic severe aortic stenosis 
 uncontrolled symptomatic heart failure 
 acute pulmonary embolus or pulmonary infarction 
 acute myocarditis or pericarditis 
 suspected or known dissecting aneurysm 
 acute systemic infection, accompanied by fever, body aches, or swollen lymph 
glands 
 severe atrial hypertension (systolic blood pressure over 200mmHg and/or diastolic 
blood pressure over 110mmHg) at rest 
 uncontrolled metabolic disease (thyrotoxicosis, or myxedema) 
 uncontrolled diabetes (HbA1c > 11%) 
 chronic infectious disease (HIV, etc.) 
 cancers requiring treatment in the past 5-years 
 women: pregnant or plan on being pregnant in the next 12 months 
 women: pre- or perimenopausal 
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Table 3.2. Participant Characteristics by Physical Activity and Sarcopenia Status 
 All 
Very 
Sedentary 
(<2500 
steps/day) 
Sedentary          
(2500-4999 
steps/day) 
Active 
 (≥5000 
steps/day) p-value Sarcopenic Not Sarcopenic p-value 
n 304 44 140 120  33 271  
Age 72.8 (5.8) 76.1 (7.1) 72.3 (5.2) 70.7 (5.3) <.0001 74.8 (6.3) 71.9 (5.7) 0.007 
Sex (% female) 58.2 (177) 27 (61.4) 79 (56.4) 71 (59.2) 0.82 69.7 (23) 56.8 (154) 0.16 
Height (cm) 168.4 (9.6) 167.6 (10.9) 168.7 (9.7) 168.2 (9) 0.8 163.9 (6.5) 168.9 (9.8) 0.01 
Weight (kg) 76.9 (16.6) 79.8 (19.4) 77.1 (16.4) 75.6 (15.6) 0.34 64.5 (9.1) 78.4 (16.7) <.0001 
Waist circumference (cm) 92.9 (14.3) 97.1 (14.6) 92.9 (14.9) 91.3 (13.1) 0.07 84.8 (11.6) 93.9 (14.3) 0.001 
Body composition         
     Body Mass Index (kg/m2) 27.0 (4.9) 28.2 (5.5) 26.9 (4.9) 26.5 (4.3) 0.14 24.0 (3.3) 27.4 (4.8) 0.0001 
     Percentage body fat (%) 39.7 (7.7) 41.7 (8.3) 39.9 (7.7) 38.7 (7.4) 0.08 40.5 (7.5) 39.6 (7.8) 0.55 
     Fat mass (g) 30179 (9739) 33325 (11621) 30278 (9584) 28909 (8950) 0.04 25851 (6671) 30706 (9929) 0.007 
     Fat free mass (g) 42876 (10030) 42773 (10278) 42882 (10097) 42907 (9945) 0.99 36389 (7234) 43666 (10046) <.0001 
     Appendicular lean mass  
     (kg/m2) 6.5 (1.2) 6.4 (1.2) 6.4 (1.2) 6.5 (1.1) 0.7 5.4 (0.7) 6.6 (1.2) <.0001 
Smoking status     0.6   0.37 
     Never 65.7 (199) 30 (68.2) 90 (64.8) 79 (65.8)  66.7 (22) 65.3 (177)  
     Current 1.0 (3) 1 (2.3) 2 (1.4) 0 (0)  3.0 (1) 0.7 (2)  
     Former 33.3 (101) 13 (29.5) 47 (33.6) 41 (34.2)  30.3 (10) 34.0 (92)  
Daily alcoholic drinks 0.5 (0.6) 0.4 (0.6) 0.4 (0.6) 0.4 (0.5) 0.75 0.5 (0.6) 0.5 (0.6) 0.94 
Heavy alcohol consumption 5.3 (16) 3 (6.8) 9 (6.4) 4 (3.3) 0.47 6.0 (2) 5.2 (14) 0.69 
Average daily calories 1791 (469) 1739 (345) 1826 (491) 1769 (486) 0.56 1717 (419) 1804 (477) 0.35 
Dietary protein intake (g/kg/day) 1.0 (0.4) 1.0 (0.3) 1.0 (0.3) 1.0 (0.3) 0.61 1.2 (0.3) 1.0 (0.4) 0.03 
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Table 3.2.   Continued 
 All 
Very 
Sedentary 
(<2500 
steps/day) 
Sedentary          
(2500-4999 
steps/day) 
Active 
 (≥5000 
steps/day) p-value Sarcopenic Not Sarcopenic p-value 
Strength         
     1 Rep. max chest press (lbs) 75.2 (37.2) 64.1 (38.4) 76.4 (37.9) 77.3 (35.6) 0.15 46.6 (19.6) 78.5 (37.4) <.0001 
     1 Rep. max leg press (lbs) 183.9 (78.0) 165.6 (93) 181.7 (76) 191.9 (74.3) 0.17 117.1 (44.7) 191.2 (77.4) <.0001 
     Grip strength (kg) 29.9 (10.3) 26.9 (10) 30.3 (10.8) 30.5 (9.5) 0.11 20.4 (6.2) 31.1 (10.1) <.0001 
Function         
     SPPB total score 11.4 (1.1) 10.5 (1.8) 11.4 (0.8) 11.6 (0.8) <.0001 11.0 (1.2) 11.4 (1.1) 0.03 
     Gait speed (m/s) 1.1 (0.2) 1 (0.1) 1.1 (0.2) 1.04 (0.43) 0.001 1.0 (0.2) 1.2 (0.2) <.0001 
Fitness         
     400 meter walk  
     (time in min) 4.5 (0.8) 5.4 (1.2) 4.4 (0.5) 4.2 (0.5) <.0001 5.0 (0.9) 4.4 (0.8) 0.0004 
Daily steps 4943 (2632) 1703 (621) 3790 (719) 7476 (2232) <.0001 4063 (2213) 5050 (2663) 0.04 
Physical activity (MET-
hours/week)         
     Vigorous aerobic 14.1 (18.7) 6.4 (11.8) 12.7 (18) 18.5 (20.2) 0.001 13.0 (17.8) 14.3 (18.8) 0.72 
     Moderate aerobic 81.7 (65.5) 81 (65.3) 74.6 (66) 90.2 (64.4) 0.16 73.0 (67.5) 82.8 (65.3) 0.42 
     Light aerobic 67.3 (36.4) 73.5 (34.4) 64 (38.3) 68.7 (34.5) 0.27 66.1 (26.7) 67.4 (37.4) 0.85 
     Resistance time 17.7 (23.1) 21.9 (38) 17.9 (22.9) 15.7 (14.5) 0.31 10.2 (14.8) 18.6 (23.8) 0.049 
     Sedentary time (hrs/day) 11.9 (5.0) 13.3 (6.3) 12.2 (4.8) 10.8 (4.3) 0.008 10.6 (4.0) 12.0 (5.1) 0.13 
Self-reported health     0.006   0.60 
     Excellent 0.7 (2) 1 (2.3) 1 (0.7) 0 (0)  0.0 (0) 0.7 (2)  
     Very good 25.3 (77) 9 (20.5) 30 (21.4) 38 (31.7)  21.2 (7) 25.8 (70)  
     Good 53.3 (162) 19 (43.2) 83 (59.3) 60 (50.0)  51.5 (17) 53.5 (145)  
     Fair 19.4 (59) 12 (27.3) 26 (18.6) 21 (17.5)  24.2 (8) 18.8 (51)  
     Poor 1.3 (4) 3 (6.8) 0 (0) 1 (0.8)  3.0 (1) 1.1 (3)  
Health-related Quality of Life  
     (SF-36) 725 (92) 664 (110) 724 (95) 747 (70) <.0001 723 (72) 725 (94) 0.9 
Geriatric Depression Scale  
     (GDS) 0.9 (1.4) 1.1 (1.1) 0.8 (1.3) 0.7 (1.5) 0.46 0.8 (1.4) 0.9 (1.4) 0.62 
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Table 3.2.   Continued 
 All 
Very 
Sedentary 
(<2500 
steps/day) 
Sedentary          
(2500-4999 
steps/day) 
Active 
 (≥5000 
steps/day) p-value Sarcopenic Not Sarcopenic p-value 
Education     0.73   0.49 
     High School 12.2 (37) 6 (13.6) 14 (10.0) 17 (14.2)  6.1 (2) 12.9 (35)  
     College 39.5 (120) 19 (43.2) 58 (41.4) 43 (35.8)  39.4 (13) 39.5 (107)  
     Graduate 48.4 (147) 19 (43.2) 68 (48.6) 60 (50.0)  54.6 (18) 47.6 (129)  
Income     0.24   0.93 
     Low (<$50,000) 17.0 (59) 9 (21.4) 30 (3.7) 11 (9.5)  9.7 (3) 17.8 (47)  
     Moderate ($50,000 - 74,999) 22.6 (67) 10 (23.8) 31 (22.6) 26 (22.4)  22.6 (7) 22.7 (60)  
     High (≥$75,000) 60.4 (178) 23 (54.8) 76 (55.5) 79 (70.1)  67.7 (21) 58.5 (157)  
Comorbidities     0.04   0.53 
     0 74.9 (218) 24 (57.1) 104 (77.0) 90 (79.0)  68.8 (22) 75.7 (196)  
     1 19.2 (56 12 (28.6) 24 (17.8) 20 (17.5)  21.9 (7) 18.9 (49)  
     2 5.5 (16) 5 (11.9) 7 (5.2) 4 (3.5)  9.4 (3) 5.0 (13)  
     3 0 (0) 0 (0) 0 (0) 0 (0)  0 (0) 0 (0)  
     4 0.3 (1) 1 (2.4) 0 (0) 0 (0)  0 (0) 0.4 (1)  
Data are presented as mean (SD) or % (n).  Heavy alcohol consumption was considered >14 & >7 alcohol drinks per week for males 
and females, respectively. SPPB: Short Physical Performance Battery. MET: Metabolic Equivalent. Comorbidities include: 
Myocardial infarction, Congestive heart failure, Heart arrhythmia, Stroke, Abnormal ECG, Type 2 Diabetes, and Chronic Obstructive 
Pulmonary Disease. 
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Table 3.3. Sarcopenia Definitions 
Definition Diagnostic Criteria 
  Physical 
Function 
(Gait Speed)  
Muscle Strength                
(Handgrip Strength)  
Muscle Mass                                     
(Appendicular Lean 
Mass) 
EWGSOP 
≤0.8m/s OR 
Female <20kg, 
Male <30kg AND 
DXA ALM/ht2 
Female: ≤5.67,  
Male: ≤7.23 
IWGS 
<1.0m/s 
  
AND 
DXA ALM/ht2 
Female: ≤5.67,  
Male: ≤7.23 
FNIHSP 
≤0.8m/s AND 
Female <16kg, 
Male <26kg AND 
DXA ALM/BMI 
Female: <0.512,  
Male: <0.789 
FNIHSPRevised 
≤0.8m/s AND 
Female <19.99kg, 
Male <31.83kg AND 
DXA ALM/BMI 
Female: <0.591,  
Male: <0.725 
EWGSOP: European Working Group on Sarcopenia in Older People, IWGS: International 
Working Group on Sarcopenia, FNIHSP: Foundation for the National Institutes of Health 
Sarcopenia Project, FNIHSPRevised: revised definition includes less conservative cut-points for 
handgrip strength and ALM, m/s: meters per second, kg: kilogram, DXA: Dual X-ray 
Absorptiometery, ALM/ht2: appendicular lean mass normalized by height squared, BMI: 
Body Mass Index. 
 
Table 3.4. Prevalence of Sarcopenia by Clinical Definition, Age, and Sex 
Definition Prevalence  
All Females Males  
65-69 70-79 ≥80 65-69 70-79 ≥80 
EWGSOP 
33/304 
(10.9%) 
5/73 
(6.9%) 
14/78 
(18.0%) 
4/26 
(15.4%) 
3/50 
(6.0%) 
5/59 
(8.5%) 
2/18 
(11.1%) 
IWGS 
29/304 
(9.5%) 
3/73 
(4.1%) 
10/78 
(12.8%) 
4/26 
(15.4%) 
3/50 
(6.0%) 
6/59 
(10.2%) 
3/18 
(16.7%) 
FNIHSP 
2/304 
(0.6%) 
0/73 
(0.0%) 
0/78 
(0.0%) 
1/26 
(3.9%) 
0/50 
(0.0%) 
0/59 
(0.0%) 
0/18 
(0.0%) 
FNIHSPRevised 
5/304 
(1.6%) 
0/73 
(0.0%) 
1/78 
(1.3%) 
3/26 
(11.5%) 
0/50 
(0.0%) 
0/59 
(0.0%) 
1/18 
(5.6%) 
EWGSOP: European Working Group on Sarcopenia in Older People, IWGS: International 
Working Group on Sarcopenia, FNIHSP: Foundation for the National Institutes of Health 
Sarcopenia Project, FNIHSPRevised: revised definition includes less conservative cut-points for 
handgrip strength and ALM. 
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Table 3.5. Multinomial Linear Regression Analysis of Muscle Mass, Muscle Strength, and Muscle Function according to Lifestyle 
Variables 
  Variables 
Model 1 Model 2 Model 3 
β SE p 
Adj. 
R2 β SE p 
Adj. 
R2 β Standard β SE p 
Adj. 
R2 
ALM (kg/ht2)                           0.83 
  SED -0.01 0.01 0.21 0.78 -0.01 0.01 0.17 0.78 -0.004 -0.01 0.01 0.61   
  PA 0.05 0.01 0.001 0.79 0.05 0.01 0.001 0.78 0.02 0.05 0.01 0.09   
  CRF -0.22 0.06 <.0001 0.79 -0.23 0.06 0.000 0.79 -0.05 -0.03 0.07 0.47   
  STR* 0.36 0.04 <.0001 0.84 0.36 0.04 <.0001 0.83 0.33 0.23 0.04 <.0001   
 STR† 0.37 0.04 <.0001 0.83 0.37 0.04 <.0001 0.85 0.34 0.29 0.05 <.0001  
Handgrip 
Strength (kg)                           
0.62 
  SED 0.01 0.08 0.88 0.58 0.01 0.08 0.91 0.58 0.12 0.06 0.09 0.18   
  PA 0.01 0.16 0.53 0.58 0.03 0.16 0.84 0.58 -0.17 -0.04 0.17 0.33   
  CRF -3.18 0.62 <.0001 0.62 -3.18 0.67 <.0001 0.61 -3.75 -0.25 0.85 <.0001   
  STR* 2.33 0.50 <.0001 0.60 2.20 0.54 <.0001 0.60 1.67 0.14 0.55 0.003   
 STR† 2.56 0.53 <.0001 0.60 2.38 0.56 <.0001 0.60 1.78 0.18 0.59 0.003  
Usual Gait 
Speed (m/s)                           
0.14 
  SED -0.002 0.002 0.36 0.05 -0.001 0.002 0.59 0.05 -0.00004 -0.001 0.002 0.99   
  PA 0.01 0.004 0.05 0.06 0.01 0.004 0.21 0.06 -0.001 -0.001 0.01 0.90   
  CRF -0.13 0.02 <.0001 0.21 -0.12 0.02 <.0001 0.19 -0.12 -0.45 0.02 <.0001   
  STR* 0.03 0.01 <.0001 0.02 0.03 0.02 0.07 0.04 0.002 0.01 0.01 0.87   
 STR† 0.04 .01 .01 0.06 0.04 0.02 0.04 0.05 0.01 0.05 0.02 0.64  
ALM: Appendicular lean mass, SED: average hours per day, PA: average daily steps from 7 days/1000, CRF: Time to complete a 400m walk, STR: chest press and leg press 
normalized by body weight and standardized by age- and sex-specific means and SD. STR*: chest press and leg press normalized by body weight and standardized by using sex- 
age-specific values. STR†: chest press and leg press normalized by body weight.  
Model 1: age, sex, BMI, education, and income.             
Model 2: further adjusted for smoking, heavy alcohol consumption, chronic conditions, and depressive symptoms.    
Model 3: further adjusted for other exposure variables.            
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Table 3.6. Multinomial Logistic Regression Analysis of Sarcopenia According to Physical 
Activity 
 
Daily Steps 
 
All 
participants 
(N=304) 
Low 
(<2,500) 
Moderate  
(≥2,500 to <5,000) 
High  
(≥5,000) p-Trend 
Sarcopenia 
(EWGSOP) 
  
 
 
Model 1 1.0 (Ref.) 0.82 (0.26, 2.53) 0.37 (0.10, 1.31)  
Model 2 1.0 (Ref.) 1.22 (0.34, 4.36) 0.58 (0.14, 2.38) 0.24 
Low 
Muscle 
Mass 
  
  
 
Model 1 1.0 (Ref.) 0.99 (0.37, 2.62) 0.33 (0.12, 0.93) 
 
Model 2 1.0 (Ref.) 0.98 (0.36, 2.69) 0.32 (0.11, 0.93) 0.003 
Low 
Handgrip 
Strength 
  
  
 
Model 1 1.0 (Ref.) 0.46 (0.20, 1.07) 0.41 (0.16, 1.02) 
 
Model 2 1.0 (Ref.) 0.49 (0.20, 1.21) 0.45 (0.17, 1.21) 0.18 
Low Gait 
Speed 
  
  
 
Model 1 1.0 (Ref.) 0.29 (0.07, 1.12) 0.13 (0.02, 0.80) 
 
Model 2 1.0 (Ref.) 0.24 (0.05, 1.08) 0.16 (0.02, 1.01) 0.048 
Model 1: adjusted for age, sex, BMI, education, and income. 
Model 2: further adjusted for smoking, heavy alcohol consumption, chronic conditions, and 
depressive symptoms. 
ALM: Appendicular lean mass. EWGSOP: European Working Group on Sarcopenia in Older 
People.  
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Table 3.7. Multinomial Logistic Regression Analysis of Sarcopenia According to 
Cardiorespiratory Fitness 
  
All 
participants 
(N=304) 
400-Meter Walk Test Tertile   
   
 
Low Moderate High p-Trend 
Sarcopenia 
(EWGSOP)    
 
     Model 1 1.0 (Ref.) 0.20 (0.07, 0.57) 0.15 (0.04, 0.50)  
Model 2 1.0 (Ref.) 0.19 (0.06, 0.57) 0.14 (0.04, 0.50) 0.001 
Low Muscle 
Mass    
 
     Model 1 1.0 (Ref.) 0.48 (0.22, 1.08) 0.18 (0.06, 0.50) 
 
Model 2 1.0 (Ref.) 0.46 (0.20, 1.08) 0.17 (0.06, 0.50) 0.001 
Low 
Handgrip 
Strength    
 
     Model 1 1.0 (Ref.) 0.31 (0.14, 0.68) 0.27 (0.10, 0.74) 
 
Model 2 1.0 (Ref.) 0.28 (0.12, 0.63) 0.25 (0.09, 0.70) 0.003 
Low Gait 
Speed    
 
     Model 1 1.0 (Ref.) 0.74 (0.18, 3.00) 0.42 (0.06, 2.88) 
 
Model 2 1.0 (Ref.) 0.76 (0.17, 3.39) 0.50 (0.07, 3.62) 0.49 
Model 1: adjusted for age, sex, BMI, education, and income. 
Model 2: further adjusted for smoking, heavy alcohol consumption, chronic conditions, and 
depressive symptoms. 
ALM: Appendicular lean mass. EWGSOP: European Working Group on Sarcopenia in Older 
People.  
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Table 3.8. Multinomial Logistic Regression Analysis of Sarcopenia According to Sedentary 
Time 
 
Sedentary Time Categories 
 
All 
participants 
(N=304) 
High 
(≥11 hours/day) 
Moderate 
(8-10 hours/day) 
Low  
(<8 hours/day) p-Trend 
Sarcopenia 
(EWGSOP) 
  
 
 
Model 1 1.0 (Ref.) 1.43 (0.58, 3.54) 1.13 (0.39, 3.25)  
Model 2 1.0 (Ref.) 1.34 (0.52, 3.42) 1.08 (0.37, 3.15) 0.77 
Low Muscle 
Mass 
    
Model 1 1.0 (Ref.) 0.50 (0.25, 1.02) 0.42 (0.19, 0.95) 
 
Model 2 1.0 (Ref.) 0.49 (0.23, 1.004) 0.43 (0.19, 0.98) 0.02 
Low 
Handgrip 
Strength 
    
Model 1 1.0 (Ref.) 0.96 (0.45, 2.08) 1.65 (0.75, 3.62) 
 
Model 2 1.0 (Ref.) 0.84 (0.38, 1.86) 1.54 (0.70, 3.43) 0.40 
Low Gait 
Speed 
    
Model 1 1.0 (Ref.) 1.89 (0.55, 6.50) 0.45 (0.05, 3.89) 
 
Model 2 1.0 (Ref.) 2.27 (0.61, 8.45) 0.57 (0.06, 5.26) 0.98 
Model 1: adjusted for age, sex, BMI, education, income. 
Model 2: further adjusted for smoking, heavy alcohol consumption, chronic conditions, and 
depressive symptoms. 
ALM: Appendicular lean mass. EWGSOP: European Working Group on Sarcopenia in Older 
People.  
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Table 3.9. Multinomial Logistic Regression Analysis of Sarcopenia According to Strength 
 
Body Weight Normalized and Age- & Sex-
Standardized Strength Tertiles 
 
All 
participants 
(N=304) Low Moderate High 
 
p-Trend 
Sarcopenia 
(EWGSOP) 
  
 
 
Model 1 1.0 (Ref.) 0.51 (0.19, 1.38) 0.07 (0.01, 0.34)  
Model 2 1.0 (Ref.) 0.49 (0.18, 1.39) 0.07 (0.01, 0.35) 0.001 
Low Muscle 
Mass 
    
Model 1 1.0 (Ref.) 0.35 (0.15, 0.81) 0.12 (0.05, 0.31) 
 
Model 2 1.0 (Ref.) 0.32 (0.13, 0.77) 0.12 (0.04, 0.31) <.0001 
Low 
Handgrip 
Strength 
    
Model 1 1.0 (Ref.) 0.32 (0.14, 0.70) 0.07 (0.02, 0.23) 
 
Model 2 1.0 (Ref.) 0.31 (0.13, 0.70) 0.07 (0.02, 0.25) <.0001 
Low Gait 
Speed 
    
Model 1 1.0 (Ref.) 0.82 (0.17, 3.95) 0.78 (0.16, 3.92) 
 
Model 2 1.0 (Ref.) 0.67 (0.12, 3.92) 0.87 (0.15, 5.13) 0.88 
Model 1: adjusted for age, sex, BMI, education, and income. 
Model 2: further adjusted for smoking, heavy alcohol consumption, chronic conditions, and 
depressive symptoms. 
ALM: Appendicular lean mass. EWGSOP: European Working Group on Sarcopenia in Older 
People 
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Table 3.10. Multinomial Logistic Regression Analysis of Sarcopenia According to Strength 
 
Body Weight Normalized Strength Tertiles 
 
All 
participants 
(N=304) Low Moderate High 
 
p-Trend 
Sarcopenia 
(EWGSOP) 
  
 
 
Model 1 1.0 (Ref.) 0.11 (0.03, 0.43) 0.02 (0.003, 0.21)  
 
Model 2 1.0 (Ref.) 0.13 (0.03, 0.52) 0.02 (0.002, 0.20) 0.0003 
Low Muscle 
Mass 
    
Model 1 1.0 (Ref.) 0.38 (0.16, 0.92) 0.07 (0.02, 0.25) 
 
Model 2 1.0 (Ref.) 0.40 (0.16, 1.01) 0.07 (0.02, 0.25) <.0001 
Low 
Handgrip 
Strength 
    
Model 1 1.0 (Ref.) 0.08 (0.02, 0.25) 0.03 (0.01, 0.16) 
 
Model 2 1.0 (Ref.) 0.08 (0.02, 0.27) 0.03 (0.01, 0.18) <.0001 
Low Gait 
Speed 
    
Model 1 1.0 (Ref.) 0.27 (0.04, 1.66) 0.26 (0.02, 2.89) 
 
Model 2 1.0 (Ref.) 0.41 (0.05, 3.16) 0.77 (0.06, 9.43) 0.69 
Model 1: adjusted for age, sex, BMI, education, and income. 
Model 2: further adjusted for smoking, heavy alcohol consumption, chronic conditions, and 
depressive symptoms. 
ALM: Appendicular lean mass. EWGSOP: European Working Group on Sarcopenia in Older 
People
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Table 3.11. Joint Analysis between Physical Activity, Sedentary Time, Fitness, and Strength on Sarcopenia in 304 Older People 
  Physical Activity and Sedentary Time 
  Inactive and Sedentary Inactive and Not Sedentary Active and Sedentary Active and Not Sedentary 
n (cases) 76 (15) 108 (10) 63 (3) 57 (5) 
Odds Ratio (95% CI) 1.0 (Ref.) 0.48 (0.18, 1.29) 0.22 (0.06, 0.88) 0.50 (0.15, 1.65) 
  Physical Activity and Cardiorespiratory Fitness 
  Inactive and Unfit Inactive and Fit Active and Unfit Active and Fit 
n (cases) 79 (18) 105 (7) 25 (3) 95 (5) 
Odds Ratio (95% CI) 1.0 (Ref.) 0.15 (0.05, 0.46) 0.39 (0.09, 1.65) 0.11 (0.03, 0.41) 
  Physical Activity and Strength 
  Inactive and Weak Inactive and Strong Active and Weak Active and Strong 
n (cases) 62 (11) 98 (9) 28 (3) 86 (3) 
Odds Ratio (95% CI) 1.0 (Ref.) 0.27 (0.09, 0.82) 0.47 (0.10, 2.29) 0.10 (0.02, 0.45) 
  Sedentary Time and Cardiorespiratory Fitness 
  Sedentary and Unfit Sedentary and Fit Not Sedentary and Unfit Not Sedentary and Fit 
n (cases) 64 (13) 101(2) 40 (8) 99 (10) 
Odds Ratio (95% CI) 1.0 (Ref.) 0.04 (0.01, 0.21) 0.44 (0.13, 1.52) 0.23 (0.07, 0.74) 
  Sedentary Time and Strength 
  Sedentary and Weak Sedentary and Strong Not Sedentary and Weak Not Sedentary and Strong 
n (cases) 58 (9) 89 (3) 35 (5) 95 (9) 
Odds Ratio (95% CI) 1.0 (Ref.) 0.13 (0.03, 0.55) 0.81 (0.19, 3.45) 0.32 (0.10, 1.03) 
  Cardiorespiratory Fitness and Strength 
  Unfit and Weak Unfit and Strong Fit and Weak Fit and Strong 
n (cases) 42 (10) 40 (4) 48 (4) 144 (8) 
Odds Ratio (95% CI) 1.0 (Ref.) 0.15 (0.03, 0.73) 0.17 (0.04, 0.80) 0.08 (0.02, 0.31) 
Model adjusted for age, sex, BMI, education, income, smoking, heavy alcohol consumption, chronic conditions, and depressive symptoms. 
Inactive: <5,000 steps per day, Active: ≥5,000 steps per day. Sedentary: ≥11 hours sitting time per day. Not Sedentary: <11 hours sitting time per 
day. Unfit: Slowest tertile on 400-m walk test. Fit: Fastest two tertiles on 400-m walk test.  Weak: Bottom tertile in weight normalized and age-
/sex-specific standardized strength category. Strong: Upper two tertiles in weight normalized and age-/sex-specific standardized strength category. 
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Figure 3-1. Participant Flow 
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CHAPTER 4.    RELIABILITY AND VALIDITY OF A FULL-BODY FUNCTION 
TEST FOR POPULATION STUDIES IN SARCOPENIA 
 
Modified from a paper to be submitted to Medicine & Science in Sport & Exercise 
Nathan F. Meier1, Duck-Chul Lee1 
1 Department of Kinesiology, Iowa State University 
 
4.1 Abstract 
Purpose: to determine the reliability and validity of a new functional Get-Up test 
compared to existing tests of strength and function commonly used in research with older 
adults. 
Methods: 304 older adults, aged 65 years and older, were recruited as part of a cohort 
study on physical activity and aging.  Participants were free of severe conditions (major 
heart, psychological, degenerative, or physical impairments).  The Get-Up test was repeated 
twice as a warm-up and twice for timed trials on two separate days.  Other relevant tests were 
conducted concurrently such as isokinetic strength, 1-repetition maximum strength tests, 
handgrip strength, Short Physical Performance Battery (SPPB), and 400m walk test. 
Results:  Pairwise comparisons between Get-Up test times from the second timed trial 
and both timed trials conducted three days later revealed no differences in means, indicating 
that the Get-Up test is reliable.  The Get-Up test was moderately to strongly correlated with 
68 
 
measures of strength, function, and fitness.  The combination of several existing tests 
strongly predicted the Get-Up test (R2adj = 0.56), as part of a validity test.   
Conclusion: The Get-Up test is reliable between trials and days of measurement.  It is 
significantly correlated with other commonly used tests for strength, function, and fitness.  A 
significant amount of variance in the Get-Up test performance was accounted for by 
measures of strength, function, and fitness.  This simple test requires minimal equipment, 
personnel, and expertise, yet helps to address some limitations in existing tools designed to 
measure total body function in older adults.   
4.2 Introduction 
Identifying deficiencies in physical functioning and ability is critical in the evaluation 
of older adults.  Given the growth of the older segments of the population (1), the additional 
costs of health care, and lower quality of life associated with increased morbidity, mobility 
disability, and mortality in older adults (2), protecting physical function and strength is 
clearly a major issue. 
The role of prevention is paramount when dealing with decreased physical function 
and sarcopenia.  Maintenance of muscle mass requires drastically less effort than regaining 
substantial quantities after a loss of muscle mass has occurred (3). The functional reserve 
capacity, which relates to the additional ability above and beyond the activities of daily living 
(ADL), should be protected, given the high risk for additional time spent in the hospital and 
mortality that exists for those with little to no reserve (4). The insidious nature of sarcopenia, 
how it is typically masked by stable body weight (5), may only become apparent after a 
significant event, such as a fall occurs or disability sets in (6).      
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Physical screening is needed beyond simply surveying an individual’s ADL (7). Valid 
and reliable objective screening measures should have favorable qualities: safe, an 
established cut-point has been determined, cost-effective, and easily performed (8).  Various 
screening tools have been proposed to aid in early identification and prevention of 
sarcopenia, which ought to reduce the diagnostic burden of existing definitions, but further 
research is needed before use in the general population (3). Although handgrip strength 
provides a proxy of well-being and has predictive validity for decline in cognition, mobility, 
functional status, and mortality (9), a simple and easy whole body measure of functional 
ability may still be more applicable to sarcopenia diagnosis and prevention at the population 
level.  
To improve the ability to screen for decreased muscular strength and physical 
function, a simple Get-Up test was developed, which requires little space, equipment, and 
expertise.  The newly developed Get-Up test may help address some of the issues seen with 
existing screening, such as a floor or ceiling effects with score-based tests, and focus on a 
specific type of movement or muscle groups that may limit a test’s generalizability.  
Therefore, the purpose of this study is to determine the reliability and validity of the test 
compared to existing measures of strength and function that are commonly used in research 
with older adults. 
4.3 Methods 
Participants were recruited from a mid-west university town and surrounding 
communities through postings, advertisements and informational talks at local organizations. 
Between October 2015 and May 2016, 304 older adults, ages 65 years and older, were 
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recruited.  Participants were free of severe conditions (major heart, psychological, 
degenerative, or physical impairments) at baseline.  
Data were collected in a series of laboratory visits over the course of two weeks 
involving physical activity measurement, medical history questionnaires, body composition, 
fitness, function, and strength tests.  The Institutional Review Board at Iowa State University 
approved this study (IRB 15-430).  Procedures were fully explained to all participants.  Prior 
to participation, all individuals provided written informed consent.  See Figure 4-1 for the 
participant flow diagram. 
4.3.1 Participant Characteristics 
Height was measured using a standard stadiometer in centimeters.  Weight was 
measured with a digital scale (Cardinal Detecto 758C Digital Scale, Webb City, Mo, USA) in 
kilograms.  Body Mass Index (BMI) was calculated as weight in kilograms divided by height 
in meters squared. Waist circumference was measured in a standing position at the level of 
the umbilicus using a measuring tape after exhalation.  Measurements were taken while 
participants wore scrubs with no shoes.   
4.3.2 Comprehensive Survey 
A comprehensive survey (lifestyle, physical activity, and medical history) 
questionnaire was administered.  The detailed self-report survey asked for the average 
aerobic and resistance physical activity and sitting time in a week over the past three months 
in the four domains (work, transportation, household, and leisure time).  The survey was 
developed based on national and international physical activity questionnaires such as 
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National Health and Nutrition Examination Survey (NHANES) and International Physical 
Activity Questionnaire (IPAQ). 
4.3.3 Objectively Measured Physical Activity 
The 7-day step count was measured using an Omron accelerometer device (HJ-321, 
Omron Healthcare Co. Ltd, Kyoto, Japan).  The Omron triaxial pedometer has been validated 
and used in large clinical trials (10,11).  The multiple piezoelectric sensors capture 
acceleration waveforms to determine steps and are not restricted to specific positions on the 
participant to accurately count steps.  The monitor stores a running 7 days of step data.  
4.3.4 Subjective Health Survey 
The Short Form Health Survey (SF-36) was used as a generic measure to compare the 
relative burden of diseases and to differentiate health benefits produced by a wide range of 
treatments.  Areas of health measured include two general measures; Physical and Mental 
Health, which are broken down into further categories.  Physical health scales include 
physical functioning, role-physical, bodily pain, and general health, whereas mental health 
scales are vitality, social functioning, role-emotional, and mental health (12).  The average 
score for each of the eight subcategories were summed to get a global score (ranging from 0-
800, a higher score indicates higher perceived health). 
4.3.5 Depression Scale 
The Geriatric Depression Scale is a 15-item scale for epidemiological research 
developed by the National Institute for Mental Health.  This survey measured the frequency 
of depressive symptoms.  The questions were answered using a yes or a no.  A higher score 
(ranging from 0-15) indicates a more depressive state (13). 
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4.3.6 Dual-Energy X-ray Absorptiometry (DXA) 
The full body scan was performed on the Hologic Horizon W model DXA (Hologic 
Inc., Bedford, MA) and Apex Software (Version 5.5.3).  A trained technician performed the 
scan with the participant supine in the standard fashion and wearing scrubs.  Software 
automatically defined regions on the trunk and appendages, which were then adjusted 
manually by one trained technician.  DXA software measured whole and regional body 
composition measures, including fat mass (FM), percentage body fat (%BF), fat-free mass 
(FFM), and appendicular lean mass (ALM).  The DXA machine was calibrated daily using 
the manufacturer-provided phantom spine segment.     
4.3.7 Diet Variables 
A three-day diet record was collected from two weekdays and one weekend day and 
was entered into The Food Processor SQL version 10.14.1 (ESHA Research, Salem, OR).  
Of the 304 participants, 213 (70%) baseline diet-records had sufficient quality to be 
analyzed. Exclusion criteria for diet-records included inadequate nutrient information, 
improper recording of weekday to weekend-day ratio, and ineligible handwriting. 
4.3.8 Sarcopenia Definition 
Sarcopenia was defined following the European Working Group on Sarcopenia in 
Older People (EWGSOP) guidelines due to Caucasian population and frequent use in 
published literature (14).  Low muscle mass, low muscle function, and low muscle strength, 
the diagnostic criteria, are described above. 
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4.3.9 New Get-up Test 
The Get-Up test assessed full body musculoskeletal performance through evaluation 
of the ability to get down onto and back up from the floor as quickly as possible.  No 
prescribed method of lowering to or rising from the ground was given, but individual were 
encouraged to use their whole body both quickly and safely through the movements. The test 
was administered on a non-slippery and flat surface, on a large, padded mat, with the subject 
in non-restrictive clothing without shoes.  The evaluator explained the movement and 
instructed: “Starting standing upright, with your arms across your chest, move as quickly as 
you are able to safely from standing to a lying position and touch your hands behind your 
neck (to prevent a potential head or neck injury), then get up off the ground and return to a 
standing position and place your arms across your chest.  Before the test is timed, you will 
practice test twice to get familiar with the movements.”  Once the participant was familiar 
with the movement, the evaluator said: “3, 2, 1, GO,” and started the stopwatch.  A one-
minute break was given between trials.  The participant completed the movement and once 
their body was upright and their arms are across their chest, the evaluator stopped the 
stopwatch and recorded the time in seconds. A learning effect was mitigated by having the 
participants practice the movement twice before they would be timed.  This allowed them to 
determine a movement strategy that they would use during the timed trial.  Participants who 
would have been unable to complete a test like the Sitting-Rising test (15) due to a joint or 
other issue, were able to successfully complete the Get-Up test due to the freedom to perform 
the test as needed.  See Figure 4-2 for a graphical representation of the movement.   To 
establish test-retest reliability of the Get-up test, the protocol was repeated again three days 
later for the entire sample. 
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4.3.10 Strength Tests 
4.3.10.1 Isokinetic testing 
The Biodex System 3 (Biodex Medical Systems, Shirley, New York, USA) is an 
isokinetic dynamometer, which allows constant velocity with accommodating resistance 
throughout the range of motion of the joint.  Resistance was maintained through an electric 
servo-controlled mechanism at a constant speed.  It is considered the gold standard for 
strength measurement.  The Biodex System 3 has been tested and shown to have acceptable 
mechanical reliability and validity on position, torque, and velocity (16).  The Biodex was 
calibrated and warmed up each day before use.  The protocol was explained to participants 
before using the equipment.   
The individual was seated and secured with chest straps.  Their arm was positioned 
immediately adjacent to the lever arm.  The arm was nearly straight and the epicondyles of 
the arm were aligned with the axis of the dynamometer.  The grip was positioned such that it 
rests comfortably in the hand when in neutral position (between supine and prone).  The 
individual pulled using their biceps through 90 degrees of motion towards their shoulder with 
their hand supine, and then extended their arm using their triceps with the hand prone until 
they returned to the starting position.  Similarly, the individual’s leg was positioned 
immediately adjacent to the lever arm.  The leg was nearly straight and the epicondyles of the 
femur were aligned with the axis of the dynamometer.  The leg was strapped in just above the 
ankle joint on the lower shin.  The participant curled their leg with their hamstring muscles 
through 90 degrees of motion, and then extended their leg using their quadriceps until they 
returned to the starting position. 
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Each individual was encouraged to use maximal effort for each repetition.  The 
protocol consisted of one set of five maximal repetitions at 60 degrees per second on their 
dominant side using the biceps, triceps, quadriceps, and hamstring muscles.  Allowing for 
five repetitions reduced the learning effect that might have been present in the first few 
repetitions using a new machine.  The peak torque generated for each muscle group during 
the set was recorded and summed to create a measure of whole body strength. 
4.3.10.2 One repetition maximum test (1RM) chest and leg press 
ACSM guidelines were followed to determine muscular strength from 1RM chest and 
leg press (17).  The participant was given three progressive warm-up sets each followed by a 
short rest.  The 1RM was determined within four trials with rest periods of 2 min between 
trials.  The initial weight was selected to be within the individual’s perceived capacity, and 
then resistance was progressively increased until the subject could not complete the repetition 
throughout the whole range of motion.  The final weight lifted successfully was the 
individual’s 1RM.  Total weight from both tests were summed to get a single score of upper 
and lower body strength. 
4.3.10.3 Handgrip strength 
Handgrip strength was measured using a digital dynamometer (Jamar Plus+, 
Lafayette Instrument, Lafayette, IN, USA).  The width of the device was adjusted to the size 
of the participant’s hand such that the middle phalanx rests on the inner handle (18).  
Participants sat and held their elbow joint at a right angle and gripped the dynamometer for 
two seconds using each hand with maximal effort.  The best of three trials with one-minute 
rest between trials was recorded for each hand (19).  
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4.3.11 Physical Function and Fitness Tests 
4.3.11.1 Short Physical Performance Battery (SPPB) 
The SPPB is a short series of tests (balance, 4-meter gait speed, and chair stand) that 
gives a composite score (20).  Tests are weighted equally with a score between zero and four, 
and a higher score indicating higher function (total ranging from 0-12).  The participant’s 
usual gait speed was measured over four meters.  Participants began walking at the start line 
and were instructed not to decelerate before crossing the finish line.  Walking aids were 
allowed if used in everyday life. Time to complete the 4-m course was recorded.  The 
repeated chair stand test was the time it took for the subject to stand up from a seated position 
five times in a row without stopping or using their arms.  The balance test consisted of 
holding three standing positions for time: 1. side by side, 2. heel of foot beside toe of the 
other foot, 3. heel of foot in front of other foot.   
4.3.11.2 400-Meter Walk Test 
The 400m walk test was the time required to walk 10 laps as fast as possible on a 20m 
long course (21).  Rests of up to 60 seconds while standing were permitted.  The test was 
conducted in a long hallway that is approximately five feet wide.  Cones marked the ends of 
the course.  The researcher told the participant the number of laps completed and remaining 
each round.  
4.3.12 Statistical analysis 
Data are presented as mean ± standard deviation or %(n).  Participant characteristics 
are displayed for the whole sample as well as compared between Get-Up test groups.  
Differences between Get-Up test groups are compared using analysis of variance, and chi-
squared tests for continuous and categorical variables, respectively.  Reliability of the Get-Up 
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test was examined using Pearson’s Correlation Coefficient and repeated measures analysis of 
variance applying multiple Get-Up tests.  Validity of the Get-Up test was explored through 
Pearson’s Correlation Coefficient, simple linear regression, and multiple linear regression in 
comparison with commonly used strength, function, and fitness tests.  Significance was set at 
a p-value of <0.05.  Statistical analysis was performed using SAS 9.4 (SAS Institute Inc., 
Cary, NC, USA).  
4.4 Results 
Participants (see Table 4.1) had a mean age of 72.8±5.8 years (range 65-96), were 
nearly all Caucasian (>99%), were 58% female, and had slightly elevated body mass index 
(27±4.9 kg/m2).  33% were former smokers (only 1% current smokers), accumulated a low 
amount of daily steps (4943±2632 steps/day), reported high levels of physical activity, were 
relatively high function (94% scored ≥10 on SPPB, ranging from 5 to 12), and reported good 
to excellent health (99%) at baseline.  There was a low prevalence of comorbidities (72% 
without major chronic diseases) and low levels of depressive symptoms. 88% were college 
educated and 81% earned more than $50,000 annual household income.  Across the Get-Up 
test tertiles the groups differed in all variables except for weight, waist circumference, 
moderate and light aerobic and resistance activity, depressive symptoms, education, income, 
and comorbidities.   
4.4.1 Get-up Test Reliability 
The Get-Up test protocol included four total attempts in each assessment.  The first 
two attempts were untimed and the participant was encouraged to develop their own strategy 
to get down to the floor and back up safely, but quickly using their whole body strength and 
function.  The last two attempts were timed and recorded (see Table 4.2).  See Figure 4-3 for 
78 
 
the mean and standard deviation of Get-Up test times for each age and sex group.  The 
Pearson’s Correlation Coefficient and Partial Coefficient (controlling for age and sex) 
showed a very strong relationship between trials completed on the same day (r=0.96-0.97) as 
well as on different days (r=0.89-0.91) (see Tables 4.3 and 4.4).  A repeated-measures 
analysis of variance uncovered a significant main effect for both day (p<.0001) and trial 
(p=0.009), but the follow-up pairwise comparisons showed that only the Day 1: Trial 1 
differed significantly from the Day 1: Trial 2 (p=0.045), Day 2: Trial 1 (p=0.0004), and Day 
2: Trial 2 (p<.0001).  No differences were revealed between Day 1: Trial 2 and Day 2: Trial 1 
(p=0.46), and Day 2: Trial 2 (p=0.052).  Therefore, we decided to use the time to complete 
the Get-Up test on Trial 2 because it was not statistically different from trials conducted on a 
different day.   
4.4.2 Get-up Test Validity 
The Get-Up test was compared to a wide range of existing tests for strength (Biodex 
isokinetic dynamometer, 1RM chest and leg press, handgrip strength), function (SPPB, usual 
gait speed), and fitness (400m walk test completed as quickly as possible).  The correlations 
were moderately (r=-0.3 to r=-0.5), but significantly negative for strength or function (as the 
time to complete the Get-Up test increases [slow Get-Up], strength/function decreases), and 
strongly (r=0.7) and significantly positive with fitness (as the time to complete the Get-Up 
test goes up, so does the time to complete the 400m walk) (see Tables 4.5 and 4.6).  When 
controlling for age and sex, all correlations remained the same or decreased slightly, except 
1-repetition maximum strength test, which was no longer significant (p=0.16). 
Simple linear regressions indicate that small to moderate amounts of variance are 
explained by the individual strength, function, and fitness tests (Table 4.7).  Further 
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assessment using a full set of comparable tests indicate a sizable amount of variance of the 
Get-Up test is explained by the predictors (Adjusted R2=0.56) (Table 4.8).  Finally, to 
understand which predictors were most influential, a stepwise regression including all 
predictors resulted in a strong simple model of handgrip strength, SPPB total, and 400m walk 
test with the same adjusted R2 value, indicating that the Get-Up test is related to strength, 
function, and fitness (Table 4.9).  Adding relevant predictors (age, sex, smoking status, heavy 
alcohol consumption, and percentage body fat) did not significantly improve the model fit 
(data not shown). 
4.5 Discussion 
The findings of the present study suggest that the Get-Up test is reliable both between 
trials and across time when using the second of the two timed trials.  Conducting two practice 
trials and two timed trials is necessary to eliminate a learning effect.  Compared to common 
measures of strength, function, and fitness, the Get-Up test shows moderate to strong 
correlations.  These individual tests also accounted for a small to moderate amount of 
variance in regression on the Get-Up test.  Combining several common tests to predict the 
Get-Up test time resulted in a strong model (R2adj = 0.56), indicating that the Get-Up test is 
related to strength, function, and fitness.  Adding additional predictor variables like age, sex, 
lifestyle, and health status did not improve the model fit.   
This proposed test is a helpful addition due to its simplicity and requiring almost no 
equipment or expertise to conduct.  Its instructions are flexible and allow individuals with a 
range of injuries, joint replacement, and medical conditions to complete the test.  Since the 
outcome is time-based, it is easy to identify even small differences in performance between 
individuals and groups, as well as changes over time.  It also mimics a movement that is a 
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typical challenge for older adults to overcome: getting up off the ground.  It also requires the 
individual to conduct a reasonably complex movement that incorporates the whole body, 
giving it a unique fit into the range of existing tests.   
This test is safe and practical for older adults.  Using a simple gymnastics-type, high-
density foam mat provided a stable, cushioned surface for the test.  Only one participant had 
an adverse event (i.e. small skin abrasion) during the more than 2,000 repetitions of this test, 
which emphasizes the need for a spotter on each side of the participant during the test to 
ensure the safety of the participant and avoid injuries resulting from loss of balance or other 
issues.   
Strengths of this study include conclusively testing reliability by conducting multiple 
trials three days apart.  A wide range of other strength, function and fitness measurements 
provided a thorough and varied set of comparisons to establish the validity of the Get-Up 
test.  These tests were performed in a large group of older adults where differences between 
function varied and were described rigorously. Finally, the test is fast, flexible, can identify 
small changes in performance time, and mimics a typical challenge for older adults in rising 
from the floor that requires complex coordination to accomplish. 
Limitations include the lack of racial diversity, high socioeconomic status, and 
general good health of the sample, which limits the generalizability to the general population. 
Despite self-reported good health, the prevalence of sarcopenia (10%) in the sample was 
typical for a group of community-dwelling older adults (22). 
To further establish the Get-Up as a relevant and powerful test related to strength, 
function, and fitness, its ability to predict other health outcomes and mortality should be 
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tested in a longitudinal cohort.  It may also be useful to explore its relationship to balance and 
fall risk. Further research should establish norms and compare Get-Up times of healthy to 
diseased populations and community-dwelling to institutionalized and hospitalized 
individuals. 
Overall, there is strong evidence for the reliability and validity of the Get-Up test as a 
measure of full-body strength, function, and fitness.   
4.6 References 
1.  Day JC. Population Projections of the United States by Age, Sex, Race, and Hispanic 
Origin: 1995 to 2050. US Bur Census, Curr Popul Reports. 1996;131 p.  
 
2.  Janssen I, Shepard DS, Katzmarzyk PT, Roubenoff R. The healthcare costs of 
sarcopenia in the United States. J Am Geriatr Soc. 2004;52(1):80–5. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14687319 
 
3.  Yu SCY, Khow KSF, Jadczak AD, Visvanathan R. Clinical Screening Tools for 
Sarcopenia and Its Management. Curr Gerontol Geriatr Res.2016:1–10.  
 
4.  de Hoogt PA, Reisinger KW, Tegels JJW, Bosmans JWAM, Tijssen F, Stoot JHMB. 
Functional Compromise Cohort Study (FCCS): Sarcopenia is a Strong Predictor of 
Mortality in the Intensive Care Unit. World J Surg. 2017; Available from: 
http://link.springer.com/10.1007/s00268-017-4386-8 
 
5.  Gallagher D, Ruts E, Visser M, Heshka S, Baumgartner RN, Wang J, et al. Weight 
stability masks sarcopenia in elderly men and women. Am J Physiol Metab. 
2000;279(2):E366–75. Available from: 
http://www.physiology.org/doi/10.1152/ajpendo.2000.279.2.E366 
 
6.  Visvanathan R, Chapman I. Preventing sarcopaenia in older people. Maturitas. 
2010;66(4):383–8.  
 
7.  Danilovich MK, Corcos DM, Marquez DX, Eisenstein AR, Hughes SL. Performance 
measures, hours of caregiving assistance, and risk of adverse care outcomes among 
older adult users of Medicaid home and community-based services. SAGE open Med. 
2015;3:1-8.  
 
8.  Grimes DA, Schulz KF. Uses and abuses of screening tests. Lancet. 
2002;359(9309):881–4. Available from: http://dx.doi.org/10.1016/S0140-
6736(02)07948-5%5Cn 
82 
 
9.  Rijk JM, Roos PR, Deckx L, van den Akker M, Buntinx F. Prognostic value of 
handgrip strength in people aged 60 years and older: A systematic review and meta-
analysis. Geriatr Gerontol Int. 2016;16(1):5–20.  
 
10.  Steeves J a, Tyo BM, Connolly CP, Gregory D a, Stark N a, Bassett DR. Validity and 
Reliability of the Omron HJ-303 Tri-Axial Accelerometer-Based Pedometer. J Phys 
Act Health. 2011;8(7):1014–20.  
 
11.  Rodriguez-Sánchez E, Criado-Gutiérrez JM, Mora-Simón S, Muriel-Diaz MP, Gómez-
Marcos M a, Recio-Rodríguez JI, et al. Physical activity program for patients with 
dementia and their relative caregivers: randomized clinical trial in Primary Health 
Care (AFISDEMyF study). BMC Neurol. 2014;14(1):63.  
 
12.  Mchorney CA, Ware JE, Lu JFR, Donald C, Rachel JF, Sherbourne CD. The MOS 36-
Item Short-Form Health Survey (SF- III. Tests of Data Quality, Scaling Assumptions, 
and Reliability Across Diverse Patient Groups. Sherb Source Med Care. 
1994;32(1):40–66.  
 
13.  Sheikh JI, Yesavage JA. Geriatric Depression Scale ( Short Form ) Geriatric 
Depression Scale ( Short Form ) Self-Rated Version. Clin Gerontol. 1986;5(4):165–73.   
 
14.  Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. 
Sarcopenia: European consensus on definition and diagnosis. Age Ageing. 
2010;39(April):412–23.  
 
15.  de Brito LBB, Ricardo DR, de Araújo DSMS, Ramos PS, Myers J, de Araújo CGS. 
Ability to sit and rise from the floor as a predictor of all-cause mortality. Eur J Prev 
Cardiol. 2012; Available from: http://www.ncbi.nlm.nih.gov/pubmed/23242910 
 
16.  Drouin JM, Valovich-McLeod TC, Shultz SJ, Gansneder BM, Perrin DH. Reliability 
and validity of the Biodex system 3 pro isokinetic dynamometer velocity, torque and 
position measurements. Eur J Appl Physiol. 2004;91(1):22–9.  
 
17.  American College of Sports Medicine. ACSM’s guidelines for exercise testing and 
prescription, 9th Ed. Wolters Kluwer/Lippincott Williams & Wilkins Health; 2013. 
p.96. 
  
18.  Bijlsma  a. Y, Meskers CGM, Ling CHY, Narici M, Kurrle SE, Cameron ID, et al. 
Defining sarcopenia: The impact of different diagnostic criteria on the prevalence of 
sarcopenia in a large middle aged cohort. Age. 2013;35(3):871–81.  
 
19.  Sousa AS, Guerra RS, Fonseca I, Pichel F, Amaral TF. Sarcopenia among hospitalized 
patients – A cross-sectional study. Clin Nutr. 2015;1–6. Available from: 
http://linkinghub.elsevier.com/retrieve/pii/S0261561414003136 
 
83 
 
20.  Guralnik M. A short physical performance battery assessing lower extremity function: 
Association with self-reported disability and prediction of mortality and nursing home 
admission. J Gerontol. 1994;49(2):85–94.  
 
21.  Rolland YM, Cesari M, Miller ME, Penninx BWJH, Atkinson H, Pahor M. Reliability 
of the 400-meter usual pace walk test as an assessment of mobility limitation in older 
adults. J Am Geriatr Soc. 2004;52:972–6.  
 
22.  Shafiee G, Keshtkar A, Soltani A, Ahadi Z, Larijani B, Heshmat R. Prevalence of 
sarcopenia in the world: A systematic review and meta- analysis of general population 
studies. J Diabetes Metab Disord. 2017;16(1):1–10.  
 
 
8
4
 
4.7 Tables and Figures  
Table 4.1. Participant Characteristics by Get-Up Test Speed 
  All Get-Up Test (Tertiles) 
    Low Moderate High p-value 
n 304 97 99 97  
Age 72.8 (5.8) 70.0 (4.6) 72.2 (5.6) 74.3 (6.3) <.0001 
Sex (% female) 58.2 (177) 59.8 (58) 44.4 (44) 25.8 (25) <.0001 
Height (cm) 168.4 (9.6) 171.3 (9.6) 168.9 (9.7) 165.7 (8.9) 0.0002 
Weight (kg) 76.9 (16.6) 76.1 (15.1) 75.9 (15.8) 78.2 (18.8) 0.57 
Waist circumference (cm) 93 (14) 90 (12) 93 (13) 95 (17) 0.10 
Smoking status     0.002 
     Never 65.7 (199) 74.2 (72) 52.5 (52) 71.9 (69)  
     Current 1.0 (3) 0.0 (0) 3.0 (3) 0.0 (0)  
     Former 33.3 (102) 25.8 (25) 44.4 (44) 28.1 (27)  
Daily alcoholic drinks 0.5 (0.6) 0.6 (0.7) 0.5 (0.6) 0.3 (0.5) 0.01 
Heavy alcohol consumption 5.3 (16) 6.19 (6) 6.1 (6) 3.1 (3) 0.54 
Average daily calories 1792 (469) 1922 (577) 1725 (382) 1737 (422) 0.02 
Dietary protein intake (g/kg/day) 1.0 (0.4) 1.1 (0.5) 1.0 (0.3) 1.0 (0.3) 0.01 
Body composition      
     Body Mass Index (kg/m2) 27.0 (4.9) 25.8 (3.8) 26.5 (4.0) 28.4 (5.9) 0.0004 
     Percentage Body Fat (%) 39.7 (7.7) 35.4 (7.0) 39.1 (6.6) 43.5 (6.9) <.0001 
     Fat Mass (g) 30179 (9739) 26371 (7306) 29172 (7849) 33760 (11317) <.0001 
     Fat Free Mass (g) 42876 (10030) 45642 (10183) 43016 (9854) 40506 (9767) <.0001 
     Appendicular Lean Mass (kg/m2) 6.5 (1.2) 6.9 (1.2) 6.5 (1.2) 6.2 (1.2) 0.002 
Strength      
     1 Rep. Max Chest Press 225 (80) 92 (40) 75 (35) 59 (28) <.0001 
     1 Rep. Max Leg Press 262 (109) 217 (79) 181 (73) 158 (69) <.0001 
     Grip strength (kg) 30 (10) 36 (10) 31 (9) 24 (8) <.0001 
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Table 4.1.   Continued   
  All Get-Up Test (Tertiles) 
   Low Moderate High p-value 
Function           
     SPPB Total Score 11.4 (1.1) 11.8 (0.6) 11.7 (0.7) 11.0 (1.3) <.0001 
     Gait speed (m/s) 1.1 (0.2) 1.2 (0.2) 1.1 (0.2) 1.1 (0.1) <.0001 
Fitness (400m walk time in seconds) 4.5 (0.8) 4.0 (0.4) 4.3 (0.4) 5.0 (0.8) <.0001 
Daily steps 4943 (2632) 5734 (2711) 4970 (2498) 4366 (2522) 0.001 
Physical activity (MET-hours / week)      
     Vigorous Aerobic 14.1 (18.7) 19.4 (20.9) 15.9 (18.9) 8.0 (14.1) <.0001 
     Moderate Aerobic 81.7 (65.5) 84.2 (60.0) 81.9 (64.9) 80.2 (70.1) 0.91 
     Light Aerobic 67.3 (36.4) 63.2 (34.5) 64.5 (36.8) 73.3 (37.3) 0.11 
     Resistance time 17.7 (23.1) 20.1 (20.7) 17.5 (19.7) 14.8 (22.4) 0.21 
     Sedentary time (hrs/day) 11.9 (5.0) 11.4 (3.7) 11.1 (4.6) 12.9 (5.4) 0.01 
Self-reported health     0.001 
     Excellent 77.0 (25.3) 0.0 (0) 0.0 (0) 1.0 (1)  
     Very good 162.0 (53.3) 39.2 (38) 25.3 (25) 14.4 (14)  
     Good 59.0 (19.4) 50.5 (49) 53.4 (53) 57.7 (56)  
     Fair 4.0 (1.3) 10.3 (10) 21.2 (21) 22.7 (22)  
     Poor 0.0 (0.0) 0 (0.0) 0 (0.0) 4.1 (4)  
Health-related Quality of Life (SF-36) 725 (92) 751 (67) 731 (89) 695 (99) <.0001 
Geriatric Depression Scale (GDS) 0.9 (1.4) 0.7 (1.1) 1.0 (1.6) 1.0 (1.5) 0.07 
Education     0.73 
     High School 12.2 (37) 10.3 (10) 13.1 (13) 13.4 (13)  
     College 39.5 (120) 35.1 (34) 41.4 (41) 40.2 (39)  
     Graduate 48.3 (147) 54.6 (53) 45.5 (45) 46.4 (45)  
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Table 4.1.   Continued      
  All Get-Up Test (Tertiles) 
   Low Moderate High p-value 
Income      0.43 
     Low (<$50,000) 16.1 (49) 8.5 (8) 18.7 (18) 21.9 (21)  
     Moderate ($50,000 - 74,999) 22.0 (67) 20.2 (19) 20.8 (20) 25.0 (24)  
     High (≥$75,000) 58.6 (178) 71.3 (67) 60.4 (58) 53.1 (52)  
Comorbidities     0.79 
     0 71.7 (218) 79.0 (75) 73.7 (70) 73.3 (66)  
     1 18.4 (56) 14.7 (14) 21.1 (20) 21.1 (19)  
     2 5.2 (16) 6.3 (6) 5.3 (5) 5.6(5)  
     3 0.0 (0) 0 (0.0) 0 (0.0) 0 (0.0)  
     4 0.3 (1) 0 (0.0) 0 (0.0) 0 (0.0)  
Sarcopenia (EWGSOP) 10.2 (30) 1.0 (3) 9.1 (9) 18.6 (18) <.0001 
Data are presented as mean (SD) or % (n).  Low: fastest tertile, Moderate: middle tertile, High: slowest tertile.  
Heavy alcohol consumption was considered >14 & >7 alcohol drinks per week for males and females, respectively. SPPB: Short 
Physical Performance Battery. MET: Metabolic Equivalent. Comorbidities include: Myocardial infarction, Congestive heart failure, 
Heart arrhythmia, Stroke, Abnormal ECG, Type 2 Diabetes, and Chronic Obstructive Pulmonary Disease. 
EWGSOP: European Working Group on Sarcopenia in Older People.
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Table 4.2. Get-Up Test Performance 
  
All   
Mean SD 
Monday PM 
Trial 1 8.1 3.7 
Trial 2 7.8 3.3 
Thursday PM 
Trial 1 7.5 3.6 
Trial 2 7.4 3.3 
 
Table 4.3. Pearson coefficient of correlation between Get-Up Test Trials 
Variables Correlation Matrix 
Day1 
Trial 1 Trial 2 
Day 2     
Trial 1 Trial 2 
Day 1      Trail 1 1.00    
                      Trial 2 0.97 1.00   
Day 2      Trial 1 0.91 0.91 1.00  
                Trial 2 0.91 0.91 0.97 1.00 
*All correlations are significant at p<0.0001. 
 
Table 4.4. Partial Pearson coefficient of correlation between Get-Up Test Trials 
Variables Correlation Matrix 
Day1 
Trial 1 Trial 2 
Day 2     
Trial 1 Trial 2 
Day1      Trail 1 1.00    
               Trial 2 0.96 1.00   
Day 2     Trial 1 0.90 0.90 1.00  
               Trial 2 0.89 0.90 0.97 1.00 
*All correlations are significant at p<0.0001. Controlling for age and sex. 
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Table 4.5. Pearson Coefficient of Correlation between Get-Up Test Trials and Other 
Measurements 
  Correlation 
Strength 
Biodex Peak Torque (kg/sec) -0.41 
1 Rep. Maximum Chest/Leg Press (lbs) -0.32 
Handgrip Strength (kg) -0.38 
Function SPPB Total (0-12) -0.49 
Fitness 400m Walk Test (min to complete) 0.70 
*All correlations are significant at p<0.0001. 
 
Table 4.6. Partial Pearson Correlation of Get-Up Test with Strength, Function, and Fitness 
Measures. 
   Correlation 
Strength 
Biodex Peak Torque (kg/sec) -0.27 
1 Rep. Maximum Chest/Leg Press (lbs) -0.09 
Handgrip Strength (kg) -0.30 
Function SPPB Total (0-12) -0.51 
Fitness 400m Walk Test (min to complete) 0.67 
*All correlations are significant at p<0.0001, except 1 Rep. Maximum Chest/Leg Press        
where p=0.16. Controlling for Age and Sex. 
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Table 4.7. Linear Regression of Comparable Tests on Get-Up Test 
Model Parameter β 
Standard 
Error p Value 
Standard 
β 
Model 
R2 
Adj. Model 
R2 
Get-Up Test =  Biodex Peak Torque (kg/sec) -0.02 0.002 <.0001 -0.41 0.17 0.17 
  1 Rep. Maximum Chest/Leg Press (lbs) -0.01 0.002 <.0001 -0.26 0.07 0.07 
  Handgrip Strength (kg) -0.12 0.02 <.0001 -0.38 0.15 0.14 
  SPPB Score (0-12) -1.66 0.17 <.0001 -0.49 0.24 0.24 
  Usual Gait Speed (m/s) -7.17 0.98 <.0001 -0.40 0.16 0.15 
  400m Walk Test (min to complete) 3.14 0.19 <.0001 0.70 0.49 0.49 
 
Table 4.8. Multiple Linear Regression of All Comparable Tests on Get-Up Test 
Model Parameter β 
Standard 
Error p Value 
Standard 
β 
Model 
R2 
Adj. Model 
R2 
Get-Up Test = Biodex Peak Torque (kg/sec) -0.0002 0.004 0.94 -0.01 
0.57 0.56 
  1 Rep. Maximum Chest/Leg Press (lbs) 0.003 0.002 0.22 0.10 
  Handgrip Strength (kg) -0.07 0.02 0.004 -0.21 
  SPPB Score (0-12) -1.02 0.17 <.0001 -0.27 
  Usual Gait Speed (m/s) -0.77 0.81 0.35 -0.04 
  400m Walk Test (min to complete) 2.52 0.26 <.0001 0.52 
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Table 4.9. Multiple Linear Regression with Stepwise Selection of All Comparable Tests on Get-Up Test 
Model Parameter β 
Standard 
Error p Value 
Standard 
β Model R2 
Adj. Model 
R2 
Get-Up Test = Intercept 9.37 2.78 <.001 0.00 
0.56 0.56 
 Handgrip Strength (kg) -0.05 0.01 <.001 -0.15 
 SPPB Score (0-12) -1.04 0.17 <.0001 -0.28 
 400m Walk Test (min to complete) 2.57 0.24 <.0001 0.52 
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Figure 4-1. Participant Flow 
 
 
Figure 4-2. Start, Middle, and End Position for the Get-Up Test 
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Figure 4-3. Get-Up Times by Sex and Age Groups 
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CHAPTER 5.    PHYSICAL ACTIVITY AND INCIDENCE OF SARCOPENIA IN 
OLDER ADULTS  
Modified from a paper to be submitted to Medicine & Science in Sport & Exercise 
Nathan F. Meier1, Duck-Chul Lee1 
1 Department of Kinesiology, Iowa State University 
 
5.1 Abstract 
Purpose: to explore the effects of physical activity (PA), as well as sedentary time 
(SED), cardiorespiratory fitness (CRF), and strength (STR), on incident sarcopenia using a 
standard definition including DXA-derived appendicular lean mass (ALM). 
Methods: Participants were 304 adults over 65 years of age at baseline.  During 
0.9±0.1 years, 22 new cases (8.9% incidence) of sarcopenia were observed in 279 (91%) 
returning participants at follow-up (mean follow-up time=0.9±0.1 years).  Individuals who 
had sarcopenia at baseline were removed (n=33).  PA was assessed using a pedometer worn 
for 7 days, SED using a survey, CRF by performance on a 400m walk test, and STR by 1-
repetition maximum chest and leg press.  Sarcopenia was defined by European Working 
Group on Sarcopenia in Older People (EWGSOP) using low appendicular lean mass 
(ALMDXA), and either low handgrip strength or slow gait speed. 
Results:  A small, but significant positive correlation between changes in STR and 
handgrip strength from baseline to follow-up was observed (r=0.15).  Each additional minute 
required to complete the CRF test (400m walk) at follow-up was significantly associated 
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with a hazard ratio (HR) (95% confidence interval [95% CI]) of 6.18 (1.13, 33.67) of 
incident sarcopenia.  Additional hours of sedentary time appeared to have a protective effect 
(HR 0.82 and 95% CI, 0.69, 0.98).  When additionally controlling for vigorous or light 
physical activity, this relationship was no longer significant.  Overall, low number of new 
cases due to a short follow-up limited the analyses. 
Conclusion:  Each additional minute needed to complete the 400m walk test (CRF 
performance) at follow-up was associated with a 6x higher risk of developing sarcopenia, 
therefore, the maintenance and improvement in fitness ought to be a priority for older adults 
in sarcopenia prevention.   
5.2 Introduction 
Sarcopenia is a syndrome characterized by progressive and generalized loss of 
skeletal muscle, accompanied by decreased strength and/or function associated with aging 
(1).  It has been long established as a significant burden to our growing older adult 
population exists both in terms of the financial burden (2) as well as the higher risk of health 
outcomes for the individual, such as falls and fractures, mobility disorders, ability to perform 
activities of daily living, disability, loss of independence, and mortality (1).  Sarcopenia has 
been recently added to the International Classification of Diseases (3), which represents a 
major step forward for its research and understanding this complex condition.  A recent 
report indicated a prevalence of approximately 10% across a wide range of studies, 
populations, and diagnostic tools (4).  Although peak physical performance may be limited 
by the aging process (5), resistance exercise in older adults provides robust improvements in 
muscular strength (6).  Both the prevention and treatment of sarcopenia considered most 
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effective are physical activity, specifically resistance training, and sufficient dietary protein 
intake (7,8), both of which lack accurate epidemiological measurement tools. 
Despite significant associations being reported between PA and sarcopenia in older 
adults from cross-section and cohort studies, there are still methodological issues with the 
existing studies (9).  Limited cohort studies on sarcopenia exist using PA as an exposure 
variable, and few have utilized objectively measured physical activity (10–13).  Most studies 
asked only one to three questions about physical activity, or used the Physical Activity Scale 
of the Elderly (PASE), which is a 12-item scale (14).   
Additionally, other relevant lifestyle predictors of sarcopenia have not been fully 
included in existing cohorts, for example, SED, CRF, and STR.  The European Working 
Group on Sarcopenia in Older People (EWGSOP) definition was used in all four cohorts 
identified above, but muscle mass was determined using three different methods, and only 
one used the standard dual X-ray absorptiometry (DXA).  The use of various measurement 
devices limits accuracy and the ability to compare and pool results.  Therefore, the purpose 
of this study was to explore effects of PA, as well as SED, CRF, and STR on incident 
sarcopenia using a standard definition using DXA-derived appendicular lean mass (ALM) in 
the same study. 
5.3 Methods 
Participants were recruited from a mid-west university town and surrounding 
communities through postings, advertisements, and informational talks in local organizations.  
Recruitment occurred from October 2015 and May 2016, including 304 long-term residents 
ages 65 years and older.  Exclusion criteria were plans to be out of the area extensively, 
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cancer treatment in the past five years, or other severe conditions that would interfere or 
make exercise unsafe and/or difficult, for example major heart, psychological, degenerative, 
or physical impairments.  
The Physical Activity and Aging Study (PAAS) participants were followed for 
approximately one year as part of an ongoing longitudinal cohort. No intervention was 
provided.  Data were collected through laboratory visits over the course of two weeks 
involving questionnaires, physical activity, body composition, fitness, physical function, and 
strength.  This study was approved by the Institutional Review Board (IRB 15-430) at Iowa 
State University.  Procedures were fully explained to all participants.  Prior to participation, 
all individuals provided written informed consent.  See Figure 5.1 for Participant Flow. 
5.3.1 Basic Anthropometrics  
Height was measured using a standard stadiometer in centimeters.  Weight was 
measured with a digital scale (Cardinal Detecto 758C Digital Scale, Webb City, Mo, USA) in 
kilograms.  Body Mass Index was calculated as weight in kilograms divided by height in 
meters squared. Waist circumference was measured in a standing position at the level of the 
umbilicus using a measuring tape after exhalation.  Measurements were taken while 
participants wore scrubs with no shoes.   
5.3.2 Exposure Variables  
5.3.2.1 Physical activity (PA) 
Daily steps were measure using a widely-used, validated, and accelerometer-based 
pedometer from Omron (Model HJ-321, Illinois, USA) (15). The pedometer, worn at waist 
level, calculated total daily steps over the course of 7 days. Overall, 94.4% had complete 
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data, 3.6% had 6 days of step data, and 2% had only 5 days.  Three categories were made 
based on published cut-points for older adults of <2,500 steps per day (low), ≥2,500-4,999 
(moderate), and ≥5,000 (high) (16). 
5.3.2.2 Sedentary time (SED) 
Sedentary time was assessed using a comprehensive survey recording weekly time 
spent on average in each of the four domains (occupational, household, leisure-time, and 
transportation) based on the Compendium of Physical Activities (17) and the International 
Physical Activity Questionnaire (18). Three categories were made based on cut-points for 
older adults of <8 hours/day (low), ≥8 and <11 hours/day (moderate), and ≥11 hours/day 
(high) (19–21).  
5.3.2.3 Fitness (CRF) 
The 400-meter walk test was the time required to complete 10 laps “as fast as 
possible” on a 20-meter long course.  Rests of up to 60 seconds while standing were 
permitted.  The test was conducted in a long hallway that was approximately five feet wide.  
Cones marked the ends of the course. The researcher told the participant the number of laps 
completed and remaining each round. Three categories were made based on tertiles (low, 
moderate, and high) of 400m walk time for the present sample.  Other existing references for 
fitness could not be applied to this sample, for instance none of the participants had the failed 
to complete the 400m walk test (22), and only two failed to complete the test at slower than 
1.19m/s (23) which indicate high mortality risk and future mobility disability, respectively. 
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5.3.2.4 Strength (STR) 
ACSM guidelines were followed to determine muscular strength from one repetition 
maximum (1RM) chest and leg press (24).  The participant was given three progressive 
warm-up sets each followed by a two minute rest.  The 1RM was determined within four 
trials with rest periods of two min between trials.  The initial weight was selected to be 
within the individual’s perceived capacity, and then resistance was progressively increased 
until the subject could not complete the repetition throughout the whole range of motion.  
The final weight lifted successfully was considered the individual’s 1RM.  The 1RMs were 
normalized by body weight (1RM/body weight), standardized ((value – mean)/SD) by age 
(65-69, 70-79, ≥80) and sex-specific mean and SD, and divided into tertiles (low, moderate, 
and high) for analysis (25,26).   
5.3.2.5 Changes in Exposure Variables 
Change values were created for each exposure variable by subtracting the baseline 
variable from the follow-up variable.  Categories were created using the lower third as 
“Loss”, the middle third as “Stable”, and upper third as “Gain” for each of the change in 
exposure variables. An alternative set of categorical variables was created considering both 
baseline and follow-up status of each exposure variables using the above cut-points, which 
led to “Remained X/Y” and “Became X/Y” (i.e. remained unfit, became unfit, became fit, 
and remained fit). 
5.3.3 Outcome Variables (Sarcopenia and its Components) 
5.3.3.1 Appendicular lean mass (ALM) (Muscle mass) 
The full body scan was performed on the Hologic Horizon W model DXA (Hologic 
Inc., Bedford, MA) and Apex Software (Version 5.5.3).  A trained technician performed the 
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scan with the participant supine in the standard fashion and wearing scrubs.  Software 
automatically defined regions on the trunk and appendages, which were then adjusted 
manually by one trained technician.  DXA software measured whole and regional body 
composition measures, including fat mass (FM), percentage body fat (%BF), fat-free mass 
(FFM), appendicular lean mass (ALM), bone mineral content, and bone mineral density.  The 
DXA machine was calibrated daily using the manufacturer-provided phantom spine segment.     
5.3.3.2 Physical performance (Muscle function) 
Usual gait speed was measured as part of the Short Physical Performance Battery 
(27), which is a series of tests (balance, 4m gait speed, and chair stand) that gives a 
composite score (range 0-12, the higher score representing higher function).  The 
participant’s usual gait speed was measured over 4m.  Participants began walking at the start 
line and were instructed to walk through the finish line as to avoid deceleration before 
completing the test.  Walking aids were allowed if used in everyday life. Time to complete 
the 4m course was recorded.  
5.3.3.3 Handgrip strength (Muscle strength) 
Handgrip strength was measured using a digital dynamometer (Jamar Plus+, 
Lafayette Instrument, Lafayette, IN, USA).  The width of the device was adjusted to the size 
of the participant’s hand such that the middle phalanx rests on the inner handle (28).  
Participants sat and held their elbow joint at a right angle and gripped the dynamometer for 
two seconds using each hand with maximal effort.  The best of three trials with one-minute 
rest between trials was used (29). 
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5.3.3.4 Sarcopenia 
Sarcopenia was defined following the EWGSOP guidelines due to Caucasian 
population and its frequent use in published literature (other definitions were calculated and 
reported briefly) (see Table 5.2).  Recent meta-analyses on sarcopenia have also used 
literature following the EWGSOP definitions for pooling of results (30,31). 
5.3.4 Covariates 
Sociodemographic, lifestyle (smoking, alcohol consumption, diet, weight history, and 
sleep), personal and family medical history, depressive symptoms (Geriatric Depression 
Scale-Short Form) (32), social support, and physical function data was collected using a 
comprehensive survey. This provided measures of income (<$12,000, $12,000-24,999, 
$25,000-49,999, $50,000-74,999, $75,000-99,999, >$100,000), education (Elementary, Jr. 
High, High School, College, Graduate School), smoking status (current smoker, not current 
smoker), heavy alcohol consumption (yes, no), and major medical conditions (0-7) including 
heart attack, heart failure, heart arrhythmia, stroke, abnormal ECG, type 2 diabetes, and 
chronic obstructive pulmonary disease.  Heavy alcohol consumption was drinking >14 drinks 
per week for men and >7 drinks per week for females (33). Major medical conditions were 
based on self-reported presence of physician-diagnosed myocardial infarction, congestive 
heart failure, heart arrhythmia, stroke, abnormal ECG, type 2 diabetes, and chronic 
obstructive pulmonary disease. Participants were asked to record their food intake for two 
weekdays and one weekend day.  Data from a 3-day diet record was entered into a nutrient 
analysis program (The Food Processor SQL version 10.14.1, ESHA Research, Salem OR) to 
breakdown the consumption of food items into energy, macronutrients, micronutrients, and 
nine protein variables. Of the 304 PASS participants, 213 (70%) baseline diet-records had 
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sufficient quality to be analyzed. Exclusion criteria for diet-records included inadequate 
nutrient information, improper recording of weekday to weekend-day ratio, and ineligible 
handwriting. 
5.3.5 Statistical analysis 
Continuous variables were presented as mean±SD and %(n) were used for categorical 
variables.  ANOVA and Χ2 tests were run to examine differences in groups, as appropriate.  
The primary outcome of the study was explored using multivariable linear regression to 
examine the association of baseline and changes in physical activity (PA), cardiorespiratory 
fitness (CRF), muscular strength (STR), and sitting time (SED) with changes in sarcopenia 
and sarcopenia components (muscle mass, function, and strength).  Pearson’s Partial 
Correlations examined the relationship between changes in exposure and outcome variables 
from baseline to follow-up.  Hazard Ratios (HRs) were calculated using Cox multivariable 
regression models to examine the associations of baseline and changes in exposure variables 
on incidence sarcopenia while controlling for potential confounding variables.  All statistical 
analyses were conducted using SAS for Windows version 9.4 (SAS Institute Inc., Cary, NC, 
USA).  The level of significance was set to p≤0.05. 
5.4 Results 
Over 91% (n=279) of the baseline participants (n=304) completed follow-up 
measurements (mean follow-up 0.91±0.09 years, range 0.74-1.44 years).  Participants with 
baseline sarcopenia (n=33) were then excluded.  Therefore, 246 participants were included 
(see Table 5.1), although for analyses including STR only 211 had complete measurements at 
baseline and follow-up since 1-repetition maximum tests were optional for participants over 
75 years of age, due to the intensity of the test. These 246 participants had a mean age of 
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72.5±5.6 years, approximately half were female (56.6%), had a BMI of 27.1±4.6, were 
relatively high function (11.5±1.1 SPPB), reported good health, and few comorbidities, low 
depressive symptoms, and high education and income.  The prevalence of sarcopenia was 
10.9% (33/304) at baseline and incidence of sarcopenia was 8.9% (22/246) at follow-up.   
Sarcopenic and non-sarcopenic participants differ on nearly half of all reported 
variables including age, sex, height, weight, ALM, smoking status, alcohol consumption, 
strength, SPPB, fitness, several measures of physical activity, health-related quality of life, 
and education.  In comparing the physical activity groups, differences were seen in 
relationship to age, several anthropometrics, SPPB score, fitness, some measures of physical 
activity and sedentary time, health-related quality of life, and depressive symptoms. 
Incidence rates are reported by different definition (see Table 5.2), where the highest 
cases were observed using the EWGSOP and IWGS definitions, and the lowest using the 
FNIHSP definition.  Most cases (EWGSOP) were observed in older women (70-79 years of 
age, 9/59=15.3% and ≥80 years of age, 9/21=42.9%).  The new cases of sarcopenia observed 
at follow-up came mostly from those who remained inactive (16/124=12.9%) and became 
inactive (4/32=12.5%), and few cases were observed in those who became active 
(1/22=4.6%) and remained active (1/68=1.5%) (see Table 5.4). 
Partial Pearson’s Correlation Coefficients were calculated for change values in 
exposure variables and sarcopenia variables adjusting for age and sex (see Table 5.3).  Only 
change in STR (bench and leg press) was significantly correlated with changes in handgrip 
strength as the sarcopenia component (r=0.15, p=0.03).   
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Hazard ratios were calculated for exposure variables (see Tables 5.5 to 5.8). No 
significant differences were observed in hazard ratio (HR) across physical activity groups or 
per 1,000-step increase in daily steps from baseline to follow-up.  It may be possible to 
conduct these analyses with a higher number of cases, for example, adding a baseline and 
follow-up from newly recruited participants.  Although, in this analysis the interpretation of 
the remained/became unfit/fit groups is not possible due to low number of cases in certain 
cells.  The same issue of low cell counts is true in all exposure variables using the 
remained/became categories.   
Individuals who increased sedentary time had a 72% lower risk for developing 
sarcopenia after adjusting for age and sex (model 1) compared to those decreased sedentary 
time (loss vs. gain), but this relationship was no longer significant after further adjustment for 
baseline sedentary time, body composition, socio-economic factors, lifestyle factors, and 
medical status  (model 2).  A one-hour increase in sedentary time from baseline to follow-up 
was associated with an 8% (model 1) and 18% (model 2) lower risk of developing 
sarcopenia.  Although, when adding vigorous or light physical activity from the same survey, 
the relationship was no longer significant, indicating that the association between sedentary 
time and incident sarcopenia is possibly confounded by physical activity, thus not 
independent of physical activity.  Moderate physical activity and time reported in resistance 
training did not change the relationship (data not shown). 
Maintaining (“stable”) or increasing (“gain”) the time to complete the 400-meter walk 
test, as a measure of CRF, was associated with higher point estimates, but not significantly 
different compared to decreasing time to completion (“loss”) (Table 5.7).  Each additional 
104 
 
minute required to complete the 400-meter walk test was associated with 6.18 times 
increased risk of developing sarcopenia during the follow-up time (model 2). 
Point estimates for strength appear to favor the “stable” or “gain” groups in strength, 
but no significant differences were observed.  The same was true for a one SD gain in 
strength.  Due to the decrease in cases of sarcopenia that was associated with the subset of 
the sample who had full measurements, the analyses had less statistical power to detect 
differences although the direction and magnitude of the finding appeared promising (14 cases 
with baseline and follow-up 1-RM strength data vs. 22 cases in the full dataset for all other 
exposures). 
5.5 Discussion 
Furthering our understanding about the relationship between health choices and 
sarcopenia, as well as the magnitude of their effects, is critical for older adult populations, 
especially given the high personal and financial costs associated with the disease (1,2).  
Therefore, the analysis of changes in physical activity, sedentary time, fitness, and strength 
can help to inform medical professionals, gerontologists, and older adults themselves to 
maintain good health in old age.  The most important finding indicates that avoiding a 
decrease in cardiorespiratory fitness may offer the most protection against sarcopenia.  Given 
an increase in hazard to develop sarcopenia of 6.18 times (95% CI: 1.13, 33.67) for each 
additional minute needed to complete a 400-meter walk, the maintenance and improvement 
in fitness ought to be a priority for this population.   
No other cohort studies were found that examined the relationship between change in 
cardiorespiratory fitness and incidence of sarcopenia.  One cohort with a 4-year follow-up 
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found that the Timed Up and Go (TUG) test, a popular test of mobility, functional 
performance, and balance for older adults, was significantly associated with incidence of 
sarcopenia in older Japanese women, using the EWGSOP definition and BIA for determining 
low ALM.  Each second slower to complete the TUG test indicated increased risk of 
sarcopenia at follow-up (11). Only one cross-sectional study on sarcopenia in older adults 
was found that reported measures of cardiorespiratory fitness.  Higher levels of physical 
fitness, measured by a battery of tests relating to balance, lower and upper body strength, 
lower and upper body flexibility, agility, walking speed, and aerobic capacity, were 
associated with lower risk of sarcopenic obesity, although the definition of sarcopenia used 
only considered BIA-derived lean and fat mass (34). Overall, the results of the present study 
agree broadly with the existing literature, suggesting that cardiorespiratory fitness may have 
a significant protective effect on sarcopenia, although more studies on this topic are needed. 
The roles of physical activity, sedentary time, and strength on the development of 
sarcopenia were less clear in this study.  Physical activity, measured by an accelerometer-
based pedometer, was used to collect 7-days of daily steps.  Given the objective nature of the 
pedometer and previous work showing a protective effect of objectively-measured physical 
activity on sarcopenia and sarcopenia variables (35,36), a significant association was 
expected.  The results indicated that a 1,000 step per day increase was not significant, but the 
distribution of cases along the changes in categories of physical activity (e.g., 
remained/became active/inactive groups) appears promising (Table 5.4).  This categorization 
may be worth examining again as the cohort grows and additional longitudinal data is 
collected.   
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Sedentary time appeared, in the present study, to have a protective effect against 
sarcopenia with an additional hour of sitting time being associated with an 18% reduction in 
hazard (0.82 (0.69, 0.98)).  This result does not agree with published literature on sedentary 
time and health outcomes (37).  Unfortunately, the measurement of SED was self-report, 
making it more prone to error.  When vigorous or light intensity physical activity from the 
survey was additionally added to the model, SED was no longer associated with lower risk, 
but adding moderate intensity or resistance training time did not change the relationship (data 
not show).  Other research exhibited detrimental effects of sedentary time on sarcopenia.  For 
example, Aggio and colleagues observed that each additional 30 minutes of sedentary time, 
using data from accelerometers, was associated with increased risk of sarcopenia (RR 1.22 
(1.07, 1.38)), but this association was no longer significant after moderate to vigorous 
physical activity was added to the model.  This effects of SED differ based on the amount of 
PA an individual accumulates as debated in a recent epidemiology publication (38). 
Changes in strength had point estimates indicating a possible protective effect of 
strength on the development of sarcopenia for both the one standard deviation increase and 
the changes based on the continuous values (e.g., “Loss”, “Stable”, and “Gain” groups), but 
did not reach significance.  Reduced statistical power may be the cause since fewer cases 
were observed in the subset of the sample that had complete strength variables at both 
baseline and follow-up.  But a recent review of randomized controlled trials (RCT) indicated 
that physical exercise consistently provided improvement in muscle mass, muscle strength, 
and physical performance in healthy older adults, although data in sarcopenic populations 
were lacking.  Some additional benefit was also observed in interventions that combined 
physical exercise with supplementation of dietary protein, creatine, or β-hydroxy-β- 
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methylbutyrate (HMB) (7).  The authors argued that the true effect of physical activity and 
nutritional supplementation was difficult to ascertain due to lack of baseline physical activity 
and nutritional status in participants. 
The incidence of sarcopenia observed in the present study (8.9%) is somewhat 
comparable with other recent studies conducted in older adults with longer follow-up times 
(10,11,39).  The incidence proportion in a group of 5,764 Icelandic older adults from the 
AGES-Reykjavik was 9.0-14.8% depending on physical activity level at a 5 year follow-up 
(10).  15.8% incidence was observed after a 4-year follow-up in older Japanese women (11).  
Finally, an incidence of 7.8% was reported in older, community-dwelling Chinese adults 
after four years of follow-up.   
Some limitations should be addressed.  The length of follow-up was relatively short 
(mean follow-up = 0.91 years) and contributed to the low number of cases.  Due to only 22 
cases of incidence sarcopenia being observed, several results with low cell counts (see Table 
4) should be carefully interpreted, and reanalyzed when the cohort has sufficient cases in 
each group in the future.  One-repetition maximum tests were optional for participants over 
75 years of age, therefore, even fewer cases were present for analyses including strength.  
Similarly, diet data was complete for only 70% of the sample, therefore, it was necessary to 
exclude it from the analyses due to reduced sample size and number of cases.   
The study had a number of strengths.  This was the only study found to collect 
objectively measured PA, as well as several other relevant predictors, including CRF, STR 
from 1RM tests, and SED.  We were able to report sarcopenia using a standard definition of 
sarcopenia (EWGSOP) using DXA-derived low muscle mass.  This standardization will 
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allow increased synthesis in published literature, given how often only partial definitions are 
used, such as only using a measure of low muscle mass to identify sarcopenic participants 
instead of low muscle mass and low muscle function or muscle strength (9).  Finally, our 
analyses controlled for a comprehensive set of relevant variables related to sarcopenia. 
Overall, CRF is the strongest predictor of incident sarcopenia.  SED appeared to have 
a protective effect but the effect was no longer significant after controlling for PA.  A larger 
sample size and longer follow-up may improve the ability to detect significant associations 
between exposure and outcome variables. 
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5.7 Tables and Figures 
Table 5.1. Participant Characteristics by Changes in Physical Activity Status and Incidence Sarcopenia 
 All 
Physical Activity Sarcopenia 
Remained 
Inactive 
Became 
Inactive 
Became 
Active 
Stayed  
Active p-value Yes No 
p-
value 
n 246 124 32 22 68  22 224  
Sarcopenia 22 16 4 1 1 <.0001    
Age 72.5 (5.6) 73.8 (5.9) 72.2 (5.3) 71.2 (4.8) 70.5 (5.0) 0.001 79.0 (5.3) 71.8 (5.3) <.0001 
Sex (% female) 56.6 (139) 55.7 (69) 65.6 (21) 59.1 (13) 52.9 (36) 0.68 81.8 (18) 54.0 (121) 0.01 
Height (cm) 168.9 (9.9) 169.2 (10.7) 168.2 (8.9) 168.6 (8.7) 169.0 (9.2) 0.96 161.9 (7.6 169.6 (9.8) 0.0004 
Weight (kg) 77.6 (16.2) 79.6 (16.8) 77.5 (17.4) 74.2 (15.1) 75.1 (14.5) 0.21 66.6 (9.6) 78.7 (16.3) 0.001 
Waist circumference (cm) 93.2 (13.9) 95.6 (14.2) 92.1 (15.2) 88.0 (15.3) 91.0 (11.3) 0.03 86.9 (10.2) 93.8 (14.0) 0.03 
Body composition          
     Body Mass Index (kg/m2) 27.1 (4.6) 27.7 (4.8) 27.3 (5.2) 26.0 (4.8) 26.2 (3.9) 0.11 25.4 (3.0) 27.2 (4.7) 0.07 
     Percentage Body Fat (%) 39.3 (7.6) 40.4 (7.5) 40.5 (7.8) 38.2 (8.5) 37.1 (7.0) 0.02 42.2 (6.1) 39.0 (7.7) 0.06 
     Fat Mass (g) 30093 (9384) 31698 (9341) 31147 (10894) 27688 (9758) 27449 (7921) 0.01 27739 (5997) 30325 (9631) 0.22 
     Fat Free Mass (g) 43464 (9996) 44037 (10432) 41062 (10458) 41830 (9007) 44080 (9216) 0.38 35690 (5917) 44228 (9997) 0.0001 
     Appendicular Lean Mass (kg/m2) 6.6 (1.2) 6.6 (1.2) 6.5 (1.1) 6.3 (1.2) 6.7 (1.1) 0.48 5.7 (0.8) 6.7 (1.2) <.0001 
Smoking status      0.66   0.05 
     Never 66.7 (164) 68.6 (85) 71.9 (23) 68.2 (15) 60.3 (41)  77.3 (17) 65.6 (147)  
     Current 0.8 (2) 1.6 (2) 0 (0) 0 (0) 0 (0)  4.6 (1) 0.5 (1)  
     Former 32.5 (80) 39.8 (37) 28.1 (9) 31.8 (7) 39.7 (27)  18.2 (4) 33.9 (76)  
Daily alcoholic drinks 0.5 (0.6) 0.5 (0.7) 0.4 (0.5) 0.5 (0.4) 0.5 (0.6) 0.79 0.2 (0.3) 0.5 (0.6) 0.04 
Heavy alcohol consumption 5.3 (13) 6.5 (8) 6.3 (2) 9.1 (2) 1.5 (1) 0.39 0 (0) 5.8 (13) 0.25 
Average daily calories 1815 (488) 1841 (494) 1650 (335) 1739 (424) 1870 (546) 0.30 1781 (437) 1819 (494) 0.76 
Dietary protein intake (g/kg/day) 1.0 (0.4) 1.0 (0.3) 0.9 (0.3) 1.0 (0.4) 1.1 (0.5) 0.13 1.1 (0.3) 1.0 (0.4) 0.31 
Strength          
     1 Rep. Max Chest Press (lbs) 78.1 (36.3) 76.7 (38.4) 66.8 (27.3) 78.6 (29.8) 85.5 (37.2) 0.11 46.3 (15.1) 80.5 (36.3) 0.0002 
     1 Rep. Max Leg Press (lbs) 191.1 (75.6) 188.9 (83.9) 177.2 (63.2) 168.6 (48.1) 208.3 (71.0) 0.09 126.1 (38.1) 196.6 (75.5) 0.0001 
     Grip strength (kg) 31.4 (10.1) 31.3 (11.0) 28.7 (7.6) 31.0 (8.7) 32.9 (9.6) 0.28 22.5 (6.2) 32.3 (10.0) <.0001 
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Table 5.1.   Continued 
  Physical Activity  Sarcopenia  
Function All 
Remained 
Inactive 
Became 
Inactive 
Became 
Active 
Stayed  
Active p-value Yes No 
p-
value 
     SPPB total score 11.5 (1.1) 11.3 (1.3) 11.4 (1.3) 11.6 (0.6) 11.8 (0.4) 0.003 10.9 (1.8) 11.5 (1.0) 0.01 
     Gait speed (m/s) 1.2 (0.2) 1.1 (0.2) 1.1 (0.1) 1.2 (0.1) 1.2 (0.1) 0.08 1.1 (0.2) 1.2 (0.2) 0.12 
Fitness          
     400 meter walk (time in min) 4.4 (0.8) 4.7 (0.9) 4.4 (0.7) 4.2 (0.5) 4.1 (0.4) <.0001 5.0 (1.1) 4.4 (0.7) 0.0003 
Daily steps 5018 (2640) 3191 (1077) 6398 (1584) 4030 (922) 8020 (2320) <.0001 3936 (2394) 5124 (2645) 0.04 
Physical activity (MET-hours / 
week)          
     Vigorous aerobic 14.6 (18.3) 10.5 (15.9) 14.0 (18.3) 12.8 (14.8) 23.0 (20.7) <.0001 5.7 (10.0) 15.5 (18.7) 0.02 
     Moderate aerobic 80.7 (61.1) 82.2 (69.6) 58.7 (48.9) 50.5 (25.1) 98.2 (50.9) 0.001 114.6 (95.1) 77.4 (55.9) 0.01 
     Light aerobic 67.2 (37.9) 68.7 (41.1) 63.4 (43.0) 55.8 (27.1) 70.1 (31.5) 0.41 85.6 (54.9) 65.4 (35.5) 0.02 
     Resistance time 19.0 (24.4) 20.8 (30.3) 10.4 (8.5) 20.0 (22.4) 19.5 (16.3) 0.19 21.2 (32.6) 18.8 (23.5) 0.67 
     Sedentary time (hrs/day) 12.0 (5.1) 13.0 (5.6) 10.8 (5.1) 11.6 (4.9) 11.0 (3.5) 0.02 12.9 (4.9) 11.9 (5.1) 0.41 
Self-reported health      0.69   0.94 
     Excellent 0.4 (1) 0.8 (1) 31.3 (10) 31.8 (7) 36.8 (25)  0 (0) 0.5 (1)  
     Very good 28.1 (69) 21.8 (27) 50.0 (16) 45.5 (10) 50.0 (34)  22.7 (5) 28.6 (64)  
     Good 54.1 (133) 58.9 (73) 15.6 (5) 22.7 (5) 13.2 (9)  59.1 (13) 53.6 (120)  
     Fair 16.3 (40) 16.9 (21) 3.1 (1) 0 (0) 0 (0)  18.2 (4) 16.1 (36)  
     Poor 1.2 (3) 1.6 (2) 0 (0) 0 (0) 0 (0)  0 (0) 1.3 (3)  
Health-related Quality of Life  
     (SF-36) 730 (89) 708 (103) 730 (77) 754 (71) 759 (61.7) 0.002 680 (98) 734 (87) 0.01 
Geriatric Depression Scale  
     (GDS) 0.8 (1.1) 0.8 (1.0) 1.0 (1.1) 1.3 (2.3) 0.5 (0.7) 0.02 1.0 (1.3) 0.8 (1.1) 0.46 
Education      0.74   0.03 
     High School 13.4 (33) 13.7 (17) 6.3 (2) 13.6 (3) 16.2 (11)  31.8 (7) 11.6 (26)  
     College 40.2 (99) 43.6 (54) 43.8 (14) 36.4 (8) 33.8 (23)  36.4 (8) 40.6 (91)  
     Graduate 46.3 (114) 42.7 (53) 50.0 (16) 50.0 (11) 50.0 (34)  31.8 (7) 47.8 (107)  
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Table 5.1.   Continued 
  Physical Activity Sarcopenia  
 All 
Remained 
Inactive 
Became 
Inactive 
Became 
Active 
Stayed  
Active p-value Yes No 
p-
value 
Income      0.49   0.20 
     Low (<$50,000) 17.6 (42) 26.2 (32) 3.3 (1) 9.5 (2) 9.1 (7)  28.6 (6) 14.2 (36)  
     Moderate ($50,000 - 74,999) 23.9 (57) 24.6 (30) 26.7 (8) 19.1 (4) 22.7 (15)  23.8 (5) 23.9 (52)  
     High (≥$75,000) 58.6 (140) 49.2 (60) 70.0 (21) 71.4 (15) 66.6 (44)  47.6 (10) 59.6 (130)  
Comorbidities      0.88   0.82 
     0 76.6 (180) 73.1 (87) 77.4 (24) 81.0 (17) 81.3 (52)  72.7 (16) 77.0 (164)  
     1 17.9 (42) 21.0 (25) 19.4 (6) 9.5 (2) 14.1 (9)  18.2 (4) 17.8 (38)  
     2 5.1 (12) 5.0 (6) 3.2 (1) 9.5 (2) 4.7 (3)  9.1 (2) 4.7 (10)  
     3 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)  0 (0) 0 (0)  
     4 0.4 (1) 0.8 (1) 0 (0) 0 (0) 0 (0)  0 (0) 0.5 (1)  
Data are presented as mean (SD) or % (n).  Heavy alcohol consumption was considered >14 & >7 alcohol drinks per week for males 
and females, respectively. SPPB: Short Physical Performance Battery. MET: Metabolic Equivalent. Comorbidities include: 
Myocardial infarction, Congestive heart failure, Heart arrhythmia, Stroke, Abnormal ECG, Type 2 Diabetes, and Chronic Obstructive 
Pulmonary Disease. 
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Table 5.2. Incidence of Sarcopenia at Follow-Up by Clinical Definition, Age, and Sex 
Definition Prevalence 
 
All 
Females Males 
  65-69 70-79 ≥80 65-69 70-79 ≥80 
EWGSOP 22/246 (8.9%) 0/59 (0.0%) 9/59 (15.3%) 9/21 (42.9%) 0/43 (0.0%) 2/50 (4.0%) 2/14 (14.3%) 
IWGS 13/251 (5.2%) 0/62 (0.0%) 5/63 (7.9%) 5/21 (23.8%) 0/43 (0.0%) 3/49 (6.1%) 0/13 (0.0%) 
FNIHSP 2/278 (0.7%) 1/64 (1.6%) 0/73 (1.3%) 1/24 (4.2%) 0/46 (2.0%) 0/55 (0.0%) 0/16 (0.0%) 
FNIHSPRevised 4/274 (1.5%) 1/64 (1.6%) 1/72 (1.4%) 2/22 (9.1%) 0/46 (0.0%) 0/55 (0.0%) 0/15 (0.0%) 
EWGSOP: European Working Group on Sarcopenia in Older People, IWGS: International Working Group on Sarcopenia, FNIHSP: 
Foundation for the National Institutes of Health Sarcopenia Project, FNIHSPRevised: revised definition includes less conservative cut-
points for handgrip strength and ALM, m/s: meters per second, kg: kilogram, DXA: Dual X-ray Absorptiometery, ALM/ht2: 
appendicular lean mass normalized by height squared, BMI: Body Mass Index 
 
Table 5.3. Pearson Partial Correlations Between Changes in Physical Activity, Sedentary Time, Fitness, and Strength and Changes in 
Muscle Mass, Muscle Strength, and Muscle Function 
  
Physical Activity 
Change 
Sedentary Time 
Change 
Fitness Change 
(completion time) 
Strength 
 Change 
Sarcopenia Variables r p Value r p Value r p Value r p Value 
Muscle Mass (ALM/ht2) Changes 0.04 0.58 0.04 0.54 0.002 0.97 -0.02 0.74 
Handgrip Strength (kg) Changes -0.01 0.82 0.05 0.41 -0.08 0.22 0.15 0.03 
Gait Speed (m/s) Changes -0.06 0.39 -0.05 0.49 -0.11 0.09 -0.01 0.86 
ALM: Appendicular Lean Mass, m/s: meters per second. Controlling for age and sex.
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Table 5.4. Incidence of Sarcopenia by Groups 
 Based on Changes in Categories 
 
Based on Changes in 
Continuous Values 
Physical Activity            
  Remained/Became Inactive 20/156 = 12.8% Remained Inactive 16/124 = 12.9% Loss 6/82 = 7.3% 
  
  Became Inactive 4/32 = 12.5% Stable 10/82 = 12.2% 
  Remained/Became Active 2/90 = 2.2% Became Active 1/22 = 4.6% Gain 6/82 = 7.3% 
  
  Remained Active 1/68 = 1.5%   
Sedentary Time      
  Remained/Became Sedentary 9/107 = 8.4% Remained Sedentary 7/80 = 8.8% Gain 13/80 = 16.3% 
  
  Became Sedentary 2/25 = 7.4% Stable 5/83 = 6.0% 
  Remained/Became Not Sedentary 13/139 = 9.4% Became Not Sedentary 8/55 = 14.6% Loss 4/83 = 4.8% 
  
  Remained Not Sedentary 5/79 = 6.0%   
Cardiorespiratory Fitness      
  Remained/Became Unfit 15/85 = 17.8% Remained Unfit 9/57 = 15.8% Loss 6/88 = 6.8% 
  
  Became Unfit 6/28 = 21.4% Stable 7/78 = 9.0% 
  Remained/Became Fit 7/161 = 4.4% Became Fit 0/13 = 0.0% Gain 9/80 = 11.3% 
  
  Remained Fit 7/148 = 4.7%   
Strength (n = 211, Sarcopenia Cases = 14)      
  Remained/Became Weak 10/99 = 10.1% Remained Weak 2/28 = 7.1% Loss 4/69 = 5.8% 
  
  Became Weak 0/36 = 0.0% Stable 4/71 = 5.6% 
  Remained/Became Strong 12/147 = 8.2% Became Strong 4/21 = 19.1% Gain 6/71 = 8.5% 
    
 Remained Strong 8/126 = 6.4%   
 
Remained and Became refer to staying in the same group from baseline to 12-month follow-up and changing groups from baseline to follow-up. 
Inactive: <5,000 steps per day, Active: ≥5,000 steps per day. Sedentary: ≥11 hours sitting time per day. Not Sedentary: <11 hours sitting time per 
day. Unfit: Slowest tertile on 400-m walk test. Fit: Fastest two tertiles on 400-m walk test.  Weak: Bottom tertile in weight normalized and age-
/sex-specific standardized strength category. Strong: Upper two tertiles in weight normalized and age-/sex-specific standardized strength category. 
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Table 5.5. Hazard Ratios of Sarcopenia by Changes in Physical Activity in 246 Older Adults 
  Model 1 Model 2   Model 1 Model 2 
Loss 1.0 (Ref.) 1.0 (Ref.)   Remained Inactive 1.0 (Ref.) 1.0 (Ref.) 
Stable 1.88 (0.66, 5.32) 2.36 (0.47, 12.01)   Became Inactive 0.77 (0.25, 2.40) 0.25 (0.03, 1.95) 
Gain 1.61 (0.50, 5.17) 1.75 (0.37, 8.42)   Became Active 0.58 (0.07, 4.61) 0.33 (0.03, 3.37) 
Per 1,000 Step Increase 1.07 (0.83, 1.36) 1.07 (0.70, 1.64)   Remained Active 0.17 (0.02, 1.31) 0.04 (0.001, 1.72) 
Model 1: adjusted for age and sex.      
Model 2: additionally adjusted for baseline PA, BMI, education, income, smoking status, heavy alcohol consumption, chronic 
conditions, and depressive symptoms. 
 
Table 5.6. Hazard Ratios of Sarcopenia by Changes in Sedentary Time in 246 Older Adults 
 
Model 1 Model 2 
 
Model 1 Model 2 
Loss 1.0 (Ref.) 1.0 (Ref.)   Remained Sedentary 1.0 (Ref.) 1.0 (Ref.) 
Stable 0.42 (0.15, 1.23) 0.47 (0.11, 2.09)   Became Sedentary 0.40 (0.08, 2.09) 0.20 (0.01, 4.76) 
Gain 0.28 (0.09, 0.88) 0.34 (0.06, 1.74)   Became Not Sedentary 1.20 (0.43, 3.36) 1.68 (0.32, 8.82) 
Per 1 Hour Increase 0.92 (0.85, 0.99) 0.82 (0.69, 0.98)   Remained Not Sedentary 0.47 (0.14, 1.42) 0.52 (0.05, 5.71) 
Model 1: adjusted for age and sex. 
Model 2: additionally adjusted for baseline SED, BMI, education, income, smoking status, heavy alcohol consumption, chronic 
conditions, and depressive symptoms. 
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Table 5.7. Hazard Ratios of Sarcopenia by Changes in Cardiorespiratory Fitness in 246 Older Adults 
 
Model 1 Model 2 
 
Model 1 Model 2 
Loss 1.0 (Ref.) 1.0 (Ref.)   Remained Unfit 1.0 (Ref.) 1.0 (Ref.) 
Stable 1.53 (0.50, 4.68) 2.33 (0.49, 11.08)   Became Unfit 2.49 (0.86, 7.21) 30.86 (4.05, 234.27) 
Gain 1.36 (0.45, 4.10) 2.68 (0.52, 13.93)   Became Fit NA NA 
Per 1 Minute Slower 1.87 (0.64, 5.51) 6.18 (1.13, 33.67)   Remained Fit 1.13 (0.37, 3.48) 3.88 (0.36, 41.31) 
Model 1: adjusted for age and sex. 
Model 2: additionally adjusted for baseline CRF, BMI, education, income, smoking status, heavy alcohol consumption, chronic 
conditions, and depressive symptoms. 
 
 
Table 5.8. Hazard Ratios of Sarcopenia by Changes in Strength in 211 Older Adults 
 
Model 1 Model 2 
 
Model 1 Model 2 
Loss 1.0 (Ref.) 1.0 (Ref.)   Remained Weak 1.0 (Ref.) 1.0 (Ref.) 
Stable 0.83 (0.20, 3.40) 0.75 (0.10, 5.75)   Became Weak NA NA 
Gain 0.65 (0.16, 2.66) 0.29 (0.24, 3.49)   Became Strong 1.37 (0.39, 4.85) 2.06 (0.14, 29.72) 
Per 1 SD Increase 0.54 (0.14, 2.06) 0.15 (0.02, 1.37)   Remained Strong 0.59 (0.23, 1.52) 4.79 (0.23, 98.28) 
Model 1: adjusted for age and sex. 
Model 2: additionally adjusted for baseline STR, BMI, education, income, smoking status, heavy alcohol consumption, chronic 
conditions, and depressive symptoms.
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Figure 5-1. Participant Flow
120 
 
CHAPTER 6.    CONCLUSION 
Sarcopenia research has been an area of high interest over the past few decades in 
most developed countries.  Since Rosenberg’s coining of the term sarcopenia a number of 
milestones have been achieved.  The first definition of low muscle mass being the primary 
variable to define the condition has been elaborated upon and now several international 
groups define sarcopenia in specific terms including mass, strength, and/or function.  An 
international disease classification has been released for better tracking of the effects of 
sarcopenia.  Given the multifactorial nature of the etiology of sarcopenia and its close ties to 
lifestyle in both its prevention and treatment, more research needs to be done to explore these 
relationships with strong measurement devices and with randomized controlled trials and 
well-designed cohorts to observe changes and incidence of sarcopenia over time.  
To help address some of the shortfalls in the literature, our lab designed a cohort 
study.  We are able to explore the importance of physical activity, sedentary time, 
cardiorespiratory fitness, and strength on sarcopenia and sarcopenia variables.  In study 1 
(Chapter 3), we found that most modifiable risk factors including physical activity, sedentary 
time, cardiorespiratory fitness, and strength were associated with sarcopenia.  Using 
objectively measured physical activity, cardiorespiratory fitness, and strength may help to 
improve our knowledge of sarcopenia by increasing the accuracy of the measurements.  
Some additional benefit may be gained from avoiding certain thresholds of physical activity, 
sedentary time, cardiorespiratory fitness, and strength.  When participants were active, fit, 
and strong, their odds of having sarcopenia was even lower than being considered only 
active, fit, or strong, indicating potential, combined additive benefits of these factors on 
sarcopenia. 
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To improve the ability for early detection of sarcopenia, we developed a new test of 
full body function called the Get-Up test that is simple, requires little equipment, and no 
expertise to conduct the test.  This test was reliable from trial to trial and from day to day.  It 
was validated using a battery of tests of strength (peak torque from an isokinetic 
dynamometer, 1-repetition maximum chest/leg press, and handgrip strength), function 
(SPPB), and fitness (400-meter walk test).  Overall, a high amount of variance in the Get-Up 
test was predicted by handgrip strength, SPPB, and 400-meter walk, indicating that the Get-
Up test appears to be related to strength, function, and fitness.  Furthermore, a slow 
performance on the Get-Up test was associated with significantly higher prevalence and 
incidence of sarcopenia.  We hope to explore the use of this test serially over time with 
further years of data from the PAAS cohort. 
In a preliminary look at the follow-up data from PAAS, we observed the relationship 
between changes in physical activity, sedentary time, cardiorespiratory fitness, and strength 
with changes in sarcopenia status.  The incidence of sarcopenia in just under one year of 
follow-up was significantly associated with reduced fitness.  Other analyses did not reach 
significance although, some of the point estimates and the distribution of cases of sarcopenia 
did appear promising.  Overall, changes in these modifiable lifestyle variables appear to be 
linked to sarcopenia, although further large studies with a longer follow-up are clearly 
warranted.   
This dissertation contributes to the early phases of sarcopenia literature.  It 
specifically uses objectively measured lifestyle variables to improve the accuracy of the 
results.  The measurement of sarcopenia was done using a high level of accuracy (e.g., DXA) 
using an established definition of the disease.  Many existing datasets have explored these 
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relationships with subjective measurements, low quality muscle mass data, and partial or 
non-standard definitions (e.g., only use of low muscle mass to define sarcopenia).  Due to our 
prospective design, we have incorporated these strong features.  The following bullet points 
provide some recommendations and future directions for conducting sarcopenia research 
(ordered not by importance): 
 Avoid use of non-standard definitions of sarcopenia to improve the synthesis 
of published literature. 
 Avoid use of subjective tools, use objective measurements wherever possible 
to limit measurement error. 
 Consider additional variables beyond physical activity and sedentary time, 
especially given the associations found between cardiorespiratory 
fitness/strength and sarcopenia. 
 
